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Patients with systemic lupus erythematosus  (SLE) have an increased propensity 
for developing endothelial dysfunction.  Declines in endothelial derived NO production 
as evidenced by decreases in brachial artery flow mediated dilation, suggest that 
inadequate NO levels may be one mechanism whereby vascular homeostasis is perturbed 
in SLE patients.  NO modifies progression to atherogenesis through inhibition of platelet 
aggregation, smooth muscle cell proliferation, adhesion molecule expression, and 
prevention of oxLDL.  Recent studies suggest that Type I interferons and oxidative stress, 
leading to endothelial nitric oxide synthase uncoupling, are critical for accelerated 
vasculopathies observed in SLE. We postulate that two potential mechanisms are 
responsible for abnormalities observed in SLE patients, as chronic inflammation has 
pleiotropic affects.  (1) Due to the chronic immune response, increases in oxidative stress 
persist within the endothelial milieu in vivo.  Inflammatory and injurious states enhance 
vascular permeability, cytotoxicity, and inflammatory cell infiltration.  While previous 
reports in Framingham risk populations have implicated a role for eNOS uncoupling in 
advanced atherogenesis, studies examining these mechanisms in SLE are limited. 
Analysis of the effects of SLE sera on eNOS in vitro revealed an SLE-mediated induction 
of  eNOS that paralleled patient age and protein kinase R expression. Induction of eNOS 
expression in non-autoimmune populations implicated a role for increased hydrogen 
peroxide associated with eNOS uncoupling.  To support this hypothesis, flow cytometry 
analysis of NO production in SLE sera cultured HUVECs demonstrated a profound 




of the eNOS co-factor, tetrahydrobiopterin. We investigated correlations between NO 
production and eNOS mRNA levels in vitro and found no relationship between basal NO, 
however, there was a strong positive association between NO from cultures supplemented 
with L-sepiapterin and eNOS.  Thus, enhanced NO production in response to L-
sepiapterin may explain a role for eNOS uncoupling and therapeutic possibilities for 
recoupling in SLE endothelial dysfunction.  Changes in NO also coincided with enhanced 
neutrophil adhesion to the endothelial cell surface and neutrophil chemotaxis.  
 (2) Despite evidence that SLE sera modulates eNOS and NO production, specific 
inflammatory factors responsible for this phenomenon remain unclear.  Previous reports 
showing that Type I interferons negatively associated with endothelial dysfunction in 
concert with our preliminary studies showing a correlation between eNOS and PKR gene 
expression incites the hypothesis that IFNα may negatively modulate eNOS and NO 
production.  
Inhibition of eNOS expression with the addition of IFNα was both time and dose 
dependent that correlated with PKR and MX1 induction.  As a downstream consequence, 
we observed that protein, NO, and insulin induced NO levels were decreased in response 
to IFNα treatment. Additional pro-atherogenic changes occurred in response to IFNα 
stimulation in endothelial cells including decreased cGMP and ICAM-1, VCAM-1, and 
MCP-1 induction.   However, leukocyte adhesion did not change.  
Finally, we examined used PKR and NFκB knockdown studies to demonstrate 
that the removal of NFκB but not PKR, mediates IFNα effects on eNOS mRNA. In lieu 
of IFNα mediated declines in eNOS stability, our investigation into microRNA 155, a 




expression which may promote eNOS dysfunction and subsequent increases in 
endothelial dysfunction.   
Taken together, these results indicate that SLE sera and factors previously 
identified to be associated with endothelial dysfunction negatively impact NO production 
and eNOS expression in vitro. Due to differential expression of eNOS modulated by 
rIFNα and SLE serum, we hypothesize that crosstalk between oxidative stress and IFNα 
downstream signals may promote the accelerated phenotype observed in SLE patients. 
Further, therapeutic targets that alleviate oxidative stress and prevent IFNα signaling may 
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Systemic Lupus Erythematosus 
Course of Disease 
Systemic Lupus Erythematosus  (SLE) is an autoimmune disease characterized by the 
production of autoantibodies against nuclear antigens1.  Approximately 1.5 million 
Americans and 5 million people globally are living with SLE.  SLE has a striking 
propensity to affect women of childbearing years  (20 to 40 years) at a 9:1 female to male 
ratio and is more common among women of African, Asian, and Hispanic descent2, 3, 4.  
The cause of this racial and ethnic disparity remains unknown but it may be due to both 
genetic and environmental factors5, 6. Over the past 40 years, prevalence of SLE has 
nearly tripled possibly due to improvements in clinical diagnostic tools as well as a true 
increase in incidence.   
SLE is a disease of flares and remissions in which specific flare triggers vary.  
Despite the heterogeneous nature and presentation of SLE, the American College of 
Rheumatology outlined 11 specific criteria in 1997 to diagnose lupus for clinical research.  
A SLE diagnosis encompasses a diverse range of symptoms including mild skin rashes, 
discoid rash, photosensitivity, oral ulcers, and non-erosive arthritis. Severe and life-
threatening manifestations of lupus include neurological diseases such as stroke and 
psychosis, premature atherosclerosis leading to coronary artery disease and myocardial 







Overview of Immune Function in SLE 
Advances in understanding interactions between the innate and adaptive immune 
systems have unveiled potential pathways leading to the clinical syndrome of SLE.   
Adaptive and Cellular Immunity 
SLE patients display enhanced levels of apoptosis and subsequent necrosis in 
macrophages, lymphocytes, neutrophils, and monocytes8.   Upon release nuclear matter  
(i.e. self-DNA, cell nuclei, and ribonucleoprotein particles), antigen presenting cells  (i.e. 
dendritic cells  (DCs) and macrophages) phagocytose and present these cellular 
components to autoreactive T and B-lymphocytes.   
  Autoreactive B cell overactivity is crucial in the pathogenesis of SLE.  B cells 
impede normal adaptive immune responses by aiding in the production of antibodies to 
self-antigen antibodies  (“auto” antibodies specifically targeted against “self” cellular 
components), while T lymphocyte proliferation is enhanced.  T cells including CD4+, 
CD4+DR+, CD8+DR+, CD3+CD4-CD8-αβ+, CD3+CD4-CD8-γδ-, and 
CD3+CD4+CR3+ cells, play a critical role in B cell function and pathogenic antibody 
production9, 10, 11, 12.  Immune complexes are ligands that activate Fcgamma RIIA  
(FcγRIIA)13, the complement cascade, and initiate infiltration of immune cells such as T 
lymphocytes, into tissues14; these mechanisms of action promote excessive autoantibody 
production from B cells. Other factors that influence B cell function include estradiol15 
and C5a16.   Although the actual cause of lupus has gone undefined, the wide 
accumulation of evidence surrounding genetic, environmental, and hormonal influences 




hypothesis that B cell over activity may be essential for the progression from 
autoimmunity to autoimmune disease.   
As such, a number of therapies have been approved by the US Food and Drug 
Administration to target B cells and B cell activation, including an inhibitor against the B 
lymphocyte stimulator  (BLs) known at belimumab or Benlysta®17.  Another monoclonal 
antibody that targets B cell CD20  (rituximab) has been studied in randomized controlled 
trials in SLE and lupus nephritis but did not gain FDA approval for treatment of SLE18. 
Moreover, abatacept was approved for rheumatoid arthritis for blocking CD28 to impair 
T lymphocyte activation by B cells; nonetheless, it is not yet approved for use in SLE19. 
Mycophenolate mofetil, also known as MMP or MPA  (Cellcept® or Myfortic®), 
inhibits inosine monophosphate dehydrogenase  (IMPDH), the rate-limiting enzyme in de 
novo synthesis of lymphocytic purines expressing IMPDH II, which is more sensitive to 
MPA20.   FDA approved B cell targeted therapies may have contributed to the longevity 
of SLE patients, yet, autoantibodies alone cannot sustain the auto-inflammatory response 







Although the adaptive immune system largely impacts the development of SLE, it works 
synergistically with the innate immune system.  Pattern recognition receptors  (PRRs) 
serve as detectors of systemic pathogen antigens.  PRR activation yields production of 
various cytokines and chemokines that activates host innate immunity.  Toll-like 
receptors are PRRs that serve as the “bridge” connecting both innate and adaptive 
immune systems in SLE.  TLRs 7 and 9 are endosomal receptors for DNA and RNA, 
including bacterial, viral, and endogenous nucleic acids.  Immune complexes consisting 
of nucleic acid rich components of self DNA and RNA bind the Fc receptor, 
FcgammaIIRa, are endocytosed, and promote TLR7/9 activation and subsequent 
interferon alpha  (IFN-α) production. Type I interferons such as IFN-α may serve as a 
key mediator in the clinical manifestations of SLE21, 22.  
Type I Interferons in SLE 
Interferons are comprised of 3 different subgroups, including type I  (α, β, ε, κ, τ, 
δ, ζ, and ω ), type II  (IFN γ), and type III  (IFN-λ), also known as interleukin 28 and 29. 
However, discussion of subtypes II and III are beyond the scope of this dissertation.   
Amongst the plethora of immunological factors promoting dysregulation of the 
immune system in SLE patients, type I interferons such as IFNα/β are well established as 
key players in the pathogenesis of SLE. In 1969,  New Zealand Black X New Zealand 
White  (NZW/NZB) mice induced with polyinosinic:polycytidylic acid  (poly I:poly C) 
developed accelerated lupus, suggesting that IFN-α is produced in immunological 
response to nucleic acid immunization in SLE-prone mice23.  This study was followed by 




manner that correlated with disease activity and anti-dsDNA binding.  Further, this study 
challenged previous findings that by Hooks, et al.  suggesting that type II IFNs were most 
prevalent in SLE serum24, 25. These studies raised the possibility that type I IFNs were 
important in the pathogenesis and secondary clinical manifestations of SLE. 
In 1999, plasmacytoid dendritic cells were shown to produce 200 to 1000 times 
more IFN than other isolated immune cells from human blood than any other immune 
cells26. Further, pDCs are commonly identified in proximity to inflamed tissues while 
IFN-α-related interferon inducible genes are readily identified in peripheral blood 
mononuclear cells in patients with active and inactive disease27, 28. Recent evidence 
suggest that early depletion of pDCs in a BXSB lupus-prone mouse model attenuated 
development of lupus, suggesting that pDC-derived IFN-α/β signaling is important in 
initiation of disease.  
 Neutrophil-derived self-DNA released in the form of neutrophil extracellular 
traps  (NETs) have also proved to trigger pDC activation leading to subsequent IFN-α 
production. Indeed chromatin-dependent neutrophil stimulation promoted bioactive IFN-
α production. pDCs were found to be 27 times more efficient at producing IFNα, while 
neutrophils had a 100 fold-higher bioavailability in SLE blood than pDCs29.  Thus, both 
neutrophils and pDCs serve as major sources of Type I IFNs in SLE while minor sources 
include epithelial cells and fibroblasts. Although Type I IFN concentrations may vary 
depending on cell type, they have both autocrine and paracrine affects.  
IFN-α binds the heterodimer  (alpha/beta) IFN-A receptor  (IFNAR), leading to 
the induction of antiviral immune responses   Downstream molecular targets of IFN-α 




also known as protein kinase R  (PKR), and interferon-induced protein 1  (IFIT1), that 
impedes the replication abilities of viruses.   Accordingly, excessive production and 
sustained downstream signaling of the IFN-α/β receptor  (IFNAR), induced by IFNα 
may support an autoimmune response and subsequent clinical manifestations of SLE.  In 
fact, Type I IFN signature gene expression has been shown to correlate with disease 
activity and severity and with clinical manifestations of the lupus including abnormal 
vascular repair, organ damage, atherosclerosis, and endothelial dysfunction    
IFN-α in the Pathogenesis of SLE 
The impacts of IFNα on the immune system are multifactorial, possibly 
accelerating SLE disease severity and tissue organ damage.  Studies in murine models as 
well as clinical observations provide a glimpse into immune deregulation exerted by 
IFNα downstream signaling pathways. 
NZB/NZW lupus prone mice treated with IFNα adenovirus displayed somatically 
mutated IgG2a and IgG3 antibodies, while B cells had elevated TLR7 expression and 
systemically higher levels of IL-6, TNFα, and BAFF.  These animals had higher 
induction of IL-21 in T cells and T cell dependent induction of anti-dsDNA antibodies, 
leading the authors to conclude that IFN-α mediated effects are CD4-T cell dependent30.  
Complications in severe glomerulonephritis have also been attributed to higher 
plasmacytoid DCs counts correlative with interleukin-18  (IL-18), which may implicate a 
role for IFNα in lupus nephritis31.  In vitro, IFNα priming of monocytes promotes 
development of macrophage lipid uptake and subsequent foam cell formation32, while 
others have identified the presence of IFNα producing neutrophils in atherosclerotic 




fluid  (CSF) of SLE patients, with expression increased in neurons and focal 
accumulation in the microglia of brain tissues in central nervous system SLE patients33. 
Collectively, these findings support a role for IFN-α in both the pathogenesis and 
complications associated with SLE.   
 Synergy and crosstalk between innate and adaptive immune systems promote the 
development of autoimmune diseases.  However, the development of a unified proposal 
explaining susceptibility to autoimmune disease is a difficult task. Genetic, 
environmental, and hormonal factors may provide clues regarding etiology. 
 
The Role of Genetic and Environmental Factors in the Loss of Self-Tolerance 
Although an extensive review of the genetic susceptibility to systemic lupus 
erythematosus is beyond the scope of this dissertation, we must make note of the role of 
genetics in the pathogenesis of disease.  Early studies in monozygotic twins provided 
evidence the heritability of SLE34.   C1q, tartrate resistant acid phosphatase  (TRAP), and 
3 primer repair exonuclease 1  (TREX1) are single gene deficiencies highly associated 
with SLE patients35.  Moreover, over 100 genetic variants associated with SLE risk have 
been identified.  Many single gene deficiencies and genetic variants found in SLE 
patients have been associated with abnormal production of Type I interferons in SLE.   
In addition to genetic abnormalities, environmental factors are well known to 
have adverse effects on the immune system, potentially triggering a lupus-like phenotype.   
Environmental factors such as UV irradiation, certain drugs, hormones, stress, viral or 







Over the past 50 years, therapies have become more effective as evidenced by 
improvements in survival among SLE patients.  Unfortunately, these therapies tend to 
cause side effects, are excessively costly, and negatively impact the quality of life for 
lupus patients.                       
Conventional therapies for lupus patients include antimalarial drugs such as 
hydroxychloriquine  (Plaquenil), Chloroquine, and Quinacrine, and nonsteroidal anti-
inflammatory drugs  (NSAIDs).  Immunomodulatory therapies traditionally used for 
organ transplantation are used in SLE and include corticosteroids, mycophenolate mofetil, 
azathioprine, cyclosporine, and tacrolimous.  Some medications traditionally used for 
chemotherapy such as methotrexate and cyclophosphamide are also used to treat SLE.  In 
March 2011, Belimumab  (Benlysta), which enhances B cell dysfunction, was approved 
by the FDA for the treatment of autoantibody positive patients.  Conversely, clinical trials 
using IFN-α abs have proven ineffective with reducing the IFN signature in patients with 
higher levels of Type I IFNs as well as disease activity.  
 
Causes of Morbidity and Mortality in SLE 
Heterogeneity in the pathogenesis of SLE yields varied clinical manifestations of 
the disease across the adult population.  Age at diagnosis, race, and sex appear to play 
important roles in susceptibility and severity of disease as each of these components 
impact individual immunity.  Approximately one-half to two-thirds of lupus patients 




and focal proliferative lesions yielding a worse prognosis36.  In addition cardiac 
involvement is found in approximately 30-50% of SLE patients.  
Cardiovascular diseases like atherosclerosis are now the leading cause of 
premature mortality in SLE patients; still, the etiology is unclear.  Chronic inflammation 
coupled with conventional risk factors may promote atherogenesis and subsequent 
fatalities.   Clinical and laboratory investigations are needed to clearly define the 
mechanisms of interaction between Framingham risk, autoimmune disease mediators, 









































Systemic Lupus Erythematosus and Premature 
Atherosclerosis 
 
Over the past 50 years, cardiovascular diseases have emerged as the leading cause of 
death in United States and Western Europe.  This trend in disease is mainly due to 
increased consumption of processed, high glycemic index foods paired with inactivity 
resulting from industrialization.  Cerebrovascular disease and ischemic heart disease are 
the two major cardiovascular complications.   
Cardiovascular complications have recently been identified as chronic inflammatory 
diseases induced by both genetic polymorphisms and environmental changes  (i.e. diet, 
lifestyle) within the population.  Thus, it is not surprising that patients with chronic 
inflammatory autoimmune diseases, such as rheumatoid arthritis, systemic sclerosis, 
psoriatic arthritis, ankylosing spondylitis, and SLE, have more aggressive forms of 
atherosclerosis and heart disease.  For the purposes of this investigation, the 
cardiovascular disease risk in SLE patient populations is presented with an emphasis on 
risk factors that impact preclinical disease outcomes.  
 
Cardiovascular Disease Risk in the SLE Patient Population 
Improvements in immunosuppressive therapies have led to improvements in SLE 
patient survival rates37.  As a result of increased longevity, cardiovascular disease  (CVD) 
has become a major cause of morbidity and mortality in this patient population. Patients 
typically have CVD complications including accelerated atherosclerosis  (AA) and major 




likely to die from coronary heart disease while SLE patients who are premenopausal 
women, a conventionally low risk population, are 50 times more likely to have a 
myocardial infarction38. Traditional risk factors such as hypertension, elevated 
cholesterol, and insulin resistance play a major role in cardiovascular events found in 
SLE patients; nevertheless, they do not fully account for the observed MACE and 
advanced heart disease39.  Although the pathogenesis of premature vascular disease in 
SLE patients is not fully understood, multiple studies in patients have revealed an 
increased prevalence of an initial breach in vascular wall integrity and endothelial 
function, leading to altered vascular wall permeability, elasticity and thickness, and 
finally the development of atherosclerosis. Moreover, due to the inflammatory nature of 
SLE, chronic use of corticosteroids and higher levels of oxidized LDL tend to exacerbate 
vascular damage in SLE patients.  
Over the past 40 years, studies aimed at identifying subclinical disease have 
examined SLE-specific risk factors, carotid plaque changes, and altered endothelial 
function associated with myocardial infarction  (MI).  Collectively, SLE patients more 
susceptible to MI include those with traditional cardiovascular disease risk factors, a 
longer course of disease, long-term glucocorticoid treatment, chronic nephritis, 
hypercholesterolemia, hyperlipidemia, anti-phospholipid antibodies, vasculitis, and anti-
phospholipid antigens, but, the mechanisms of this increased risk are unknown.    
Common Risk Factors 
Traditional Framingham risk factors, such as age, hypertension, 
hypercholesterolemia, diabetes, hyperlipidemia, obesity, smoking, and sedentary lifestyle, 




observed in SLE patients.  While the impact of these factors in the general population is 
well established, whether these factors are primary or secondary hazards in SLE remains 
to be elucidated.  Among all risk factors, hypertension, abnormal lipid profiles, and 
hypercholesterolemia tend to be most common in SLE patients40 41, 42, 43.  Moreover, other 
studies have shown that metabolic syndrome is an important Framingham risk factor for 
predicting cardiovascular disease 44.  
Patients with SLE tend to have a higher prevalence of conventional risk factors45. Still, 
even after adjustment for Framingham risk factors, these patients still tend to have a 
higher incidence of CVD.  Not surprisingly, a retrospective population-based study 
showed that SLE patients with late onset of disease had double the mortality rates and 
CVD events of age- and risk-matched controls46.  Collectively, these studies suggest that 
SLE-specific factors must be considered when determining cardiovascular disease risk in 
this patient population.   
 
Glomerulonephritis 
Chronic kidney disease is common among SLE patients affecting between 40-60% of 
patients with SLE.  However, studies are inconsistent regarding the role of kidney 
involvement in accelerated atherosclerosis in SLE.  Conventional risk factors, including 
dyslipidemia, hypercholesterolemia, hypertension, and insulin resistance promote 
endothelial abnormalities preceding kidney disease. Thus, renal disease associations with 
cardiovascular disease may not be causative but associative. For example, a prospective 
study examining the impact of conventional cardiovascular disease risk factors on renal 




phospholipid syndrome led to a higher incidence of death and end-stage renal disease 47 
Moreover, Font, J et. al. showed that patients with hyperlipidemia and hypertension 
developed renal failure and died from subsequent cardiovascular and cerebrovascular 
complications48.  Surprisingly, a retrospective study on SLE women with end-stage renal 
disease  (ESRD) revealed that cardiovascular and cerebrovascular mortality rates were 
not greater when compared with women with ESRD due to diabetes49.  Collectively, 
these studies suggest that, although important, ESRD may be an associative but not a 




Acute administration of corticosteroids prevents disease flares in lupus while 
long-term use is associated with adverse health effects.  Moreover, the association 
between corticosteroids and atherosclerosis is complex.  Steroid therapy is introduced as 
part of a “therapeutic cocktail” to control acute disease flares.  Unfortunately, patients 
presenting with organ involvement may experience long-term use of these drugs.  Lack of 
steroids and cyclophosphamide for treatment was associated with higher rates of carotid 
plaque, suggesting that immunosuppression may prevent vascular abnormalities 50. 
However, a long duration of steroid therapy greater than a 10mg daily dose also confers 
increases in focal carotid plaque51, leading to a higher incidence of myocardial 
infarction52 and other heart disease risks, suggesting that chronic use may exacerbate 
metabolic factors.   




function in humans53, and studies suggest that glucocorticoids like dexamethasone may 
be beneficial in maintaining eNOS expression for the prevention of cyclosporine-induced 
vasoconstriction in the rat renal vasculature54. However, little is known about its impact 
on flow mediated dilation, vascular tone, and endothelial function. 
Inflammatory Mediators and Inflammation 
Pro-inflammatory pathways leading to the development of atherosclerosis have 
gained substantial interest over the past 20 years.  The development of atherosclerosis 
begins with inflammatory-mediated activation of the endothelium, which serves as the 
“gateway” for immune cells. Cytokines such as tumor necrosis factor alpha  (TNF-α) 
appear to play a role in endothelial dysfunction, the first step in the development of 
atherosclerosis.  TNF-α is especially pro-atherogenic in non-autoimmune populations 
such as health subject, and those with diabetes or ischemia/reperfusion injury55. TNF-α 
contributes to endothelial dysfunction by impairing endothelial nitric oxide synthase 
expression, phosphorylation, and enzymatic activation56.  
In addition, TNF-α enhances endothelin-1 production, ROS production, and 
thromboxane A2 receptor signaling.  Thus, the finding that anti-TNF-α improved 
endothelial function in diabetic patients is not surprising 57 58, 59.  In SLE, TNF-α levels 
coincide with soluble ICAM-1 levels and are related to enhanced endothelial cell 
activation, reflecting the presence of endothelial dysfunction60.  However, as yet 
unexamined are correlations between brachial artery flow mediated dilation, a surrogate 
marker of endothelial function, and TNF-α levels in SLE patients.  
T lymphocytes and macrophages secrete interleukin 6, a cytokine thought to play 




eNOS at the serine 1177, desphosphorylation at threonine495 61, eNOS-caveolin-1 
dissociation,62 and correlates with endothelial dysfunction in non-autoimmune 
populations63. IL-6 levels are elevated in SLE patients with higher SLEDAI scores and 
anti-dsDNA levels 64;however, its role in SLE-related endothelial dysfunction is 
unknown.  
IL-10 levels are 3-12 fold higher in SLE patients than healthy controls65and 
coincide with higher SLEDAI scores and active disease 66.  Some evidence suggests, 
however, that IL-10 protects against endothelial dysfunction by inducing endothelial 
derived nitric oxide production, preventing production of monocyte chemoattractant 
protein-1, and impairing superoxide anion production in vivo 67, 68. However, studies 
examining the role of IL-10 in SLE-related ED are missing.  
Over the past decade, studies have shown that IL-17 is involved in the 
development of vascular inflammation; but, its role in atherosclerotic plaque formation 
remains controversial.  IL-17 is abnormally elevated in lupus patients and is thought to 
play a role in the pathogenesis of SLE.  The IL-17A receptor is expressed on the 
endothelial cell surface and has pleiotropic effects on endothelial cell function.  While 
some studies show its induction of ICAM-1, VCAM-1, and a reduction in endothelial 
derived NO production, others have shown that IL-17 induces eNOS in bone marrow 
derived cells.  Moreover, IL-17A neutralization in ApoE-/- mice showed reduced 
inflammation but did not result in plaque regression 69. Further studies are needed to 
determine the role of IL-17 in SLE-related vascular ED. 
CD40 ligand has emerged as an important cell-signaling molecule essential for 




In addition to atherosclerosis, activation of the CD40 receptor, by soluble CD40 ligand  
(sCD40L) and preformed CD40L  (pCD40L), plays an important role in the pathogenesis 
of SLE.  Recent studies suggest that pCD40L, stored in Th1, Th2, Th17, and T follicular 
helper cells, is elevated in SLE patients with higher plaque levels71.  Moreover, declines 
in endothelial cell eNOS, mRNA, protein, and NO levels were observed while, 
superoxide and NADPH oxidase activity levels were enhanced. Collectively, these data 
suggest that sCD40L may play a role in SLE-related ED72  
Human C-reactive protein  (CRP) is a promiscuous molecule that correlates with 
clinical cardiovascular disease and is predictive of cardiovascular events. Over the past 
two decades, studies have shown its involvement as a negative regulator of eNOS, 
resulting in endothelial dysfunction. Human CRP impairs eNOS transcription and 
translation, preventing phosphorylation at the eNOS activation site Ser 1177.  Moreover, 
CRP attenuates NO production and promotes eNOS uncoupling, leading to endothelial 
dysfunction73, 74. Whether CRP is responsible for the endothelial dysfunction observed in 
SLE patients is not known. Studies showing elevated levels of CRP in SLE patients are 
limited and contradictory75, 76, 77, 78. 
C-reactive protein is elevated in patients with increased risk for cardiovascular 
disease and declines in endothelial progenitor cell circulation.  In SLE, CRP associates 
with clinical disease manifestations, including myocarditis, cardiac murmur, interstitial 
pulmonary fibrosis, pulmonary hypertension, gastrointestinal lupus manifestations, and 
anemia79.  
Conversely, others have shown an insignificant increase in CRP levels with lupus 




have autoantibodies against CRP78, and these associate with renal disease81.  Increased 
CRP autoantibody production may lead to enhanced CRP immune complex formation 
and subsequent immune system activation. C reactive protein was shown to reverse 
proteinuria and decrease autoantibody production in murine lupus mouse models82.  
Surprisingly, IFN-α halts CRP promoter activity, CRP secretion, and may be responsible 
for the abnormal CRP response observed in SLE83.    
Autoantibodies 
Antibodies targeting self-antigens are known as autoantibodies.  Predominantly 
found in autoimmune populations, specific autoantibodies have emerged as key players 
of accelerated atherosclerosis.  Although a plethora of autoantibodies have been 
identified in SLE patients, only a small group associates with endothelial dysfunction and 
abnormal plaque development.  These include but are not limited to: antiphospholipid  
(aPL), pro inflammatory high-density lipoprotein  (piHDL), oxidized LDL  (oxLDL), 
anti-cardiolipin, and anti-apolipoprotein A-1 autoantibodies.  
The literature is unclear about aPL-related cardiovascular complications, but to 
some degree, supports a role for β2 glycoprotein, annexin V, and cardiolipin antibodies in 
vascular endothelial dysfunction.   In general, APLs enhance superoxide and 
peroxynitrite levels, which circumvent vascular homeostasis84.  Antiphospholipid 
antibodies  (aPLs) are well established as culprits of arterial and venous thrombosis in 
patients with antiphospholipid syndrome and SLE. They include lupus anticoagulant, 
anti-cardiolipin, and anti-beta2 GPI antibodies. Thrombosis ensues due to attacks on the 
cellular phospholipid structures in the vasculature.  Roughly 30-40% of SLE patients 




evidence is missing regarding the impact of aPLs on cardiovascular disease in SLE 
patients.  Studies have shown conflicting results regarding correlations between vascular 
health and the presence of aPLs.  A prospective study examining the association between 
aPLs and various vascular complications in roughly 200 SLE patients suggested that  
aPLs were not associated with vascular abnormalities or the presence of carotid plaque 86.  
Conversely, studies conducted in patients with retinal vascular disease showed that aPLs 
was associated with retinal complications 87. Similarly, aPLs were shown to associate 
with cutaneous vascular lesions in SLE patients.  Collectively, these studies represent 
controversy surrounding the impact of aPLs on vascular disease.   
Oxidized low density lipoprotein antibodies and immune complexes have become 
increasingly important in the pathogenesis of SLE-related atherosclerosis.  Studies show 
that elevated titers of oxidized-low density lipoprotein  (oxLDL) antibodies correlate with 
IgG anti-cardiolipin antibody and IgG anti-beta2 GPI antibody 88.  High circulating IgG 
anti-oxLDL/β2GPI antibody complexes were found in both SLE and systemic sclerosis 
patients, which may reflect the prevalence of oxidative stress in patient populations with 
chronic inflammation89.  More importantly, OxLDL antibodies are associated with the 
prevalence of plaque in SLE patients, supporting their role in the pathogenesis of 
atherosclerosis , while some studies suggest that oxLDL autoantibodies may serve as an 
important biomarker of impaired endothelial-dependent flow-mediated dilation 90, 91. 
Anti-endothelial cell antibodies  (AECAs) are highly prevalent in the serum of SLE 
patients and may also be important in SLE-related vascular disease. Early studies 
examining the role of AECAs in vasculitis discovered that activation of endothelial cells 




component into the endothelium, and disruption of the endothelial cell monolayer 92.  
Moreover, others showed that AECAs may be responsible for the in situ immune 
complex formation observed in the glomerulus of the kidney and may be involved in the 
pathogenesis of glomerulonephritis 93, 94.  Conversely, more recent studies presented data 
that suggests a milder role for AECAs.  For instance, AECAs were shown to bind 
apoptotic endothelial cells but not induce apoptosis, while prospective trials examining 
the association between endothelial dysfunction and AECAs suggested that the two 
factors were independent. Moreover, AECAs were associated with SLEDAI scores but 
were not markers of endothelial cell damage 95,96.  Collectively, these data suggest that 
AECAs may not be responsible for endothelial cell damage but may be indicative of 
vascular anomalies and perhaps disease activity.  More studies are needed to provide 
definitive answers about the role of AECAs in lupus-related vascular pathologies. 
Complement Cascade 
The complement system plays a major role in the development of autoimmune 
diseases, such as SLE, as well as vascular complications like atherosclerosis.  
Complement activation can occur via three different pathways, including the classical and 
alternative, both of which lead to formation of the membrane attack complex  (MAC) and 
the mannose-binding lectin or MBL pathway. The classical pathway encompasses 
complement components C1, C2, and C4 and is activated by the presence of immune 
complexes often identified in the blood of SLE patients.   
The role of complement in the development of SLE is complex since roughly 
75% of patients with SLE are complement deficient, lacking the C3 and more commonly 




conditions, acting as an opsonin for ridding the body of cellular debris and immune 
complexes. As a result of absent early components, immune complexes can no longer 
activate the complement cascade.  Immune complexes then deposit more readily in the 
vasculature, and inflammation persists99.   
On the other hand, complement activation plays a major role in the recruitment of 
monocytes to the endothelial cell surface, leading to endothelial and smooth muscle cell 
activation.  Still a wealth of knowledge, including in vivo and in vitro data in both murine 
models and human disease, supports a role for complement in the development of 
vascular abnormalities and atherosclerosis.  
C3 deposition in the intimal and inner medial compartments increases upon 
hypercholesterolemia and the formation of atherosclerotic intimal plaque induced by a 
high fat diet in rabbits. Further, CR2-Crry treatment, which inhibits C3 activation, 
reduced atherosclerotic plaque development in Apoe-/- mice on a high fat diet. This 
change was probably due to impaired macrophage and T cell infiltration typically 
promoted by C3 cleavage. A retrospective study examining coronary arteries from 
deceased patients with ischemic heart disease showed enhanced C3 deposition, which 
correlated with the presence of atherosclerotic lesions100.   
In genetically engineered mice possessing the Sle16 locus backcrossed to a Ldlr  
(-/-) mouse model, accelerated atherosclerosis and reduced C3 levels were observed 101.  
In SLE patients, a prospective study showed that carotid intimal media thickness  (cIMT) 
correlated with C3, C4, and CH50 levels while the cIMT was best predicted by age.  
Moreover, the authors showed that small dense HDL particles were partially responsible 




complement induces atherosclerotic plaque development are unclear, studies support the 
notion that complement activation causes vascular damage and subsequent endothelial 
dysfunction in the general population. 
Lennon, P.F et al. showed that rabbit aortic rings stimulated with various 
concentrations of complement rich human serum lost the ability to respond to 
acetylcholine- and calcium-mediated relaxation.  This study suggested that complement, 
namely C5-9 and 3, may negate endothelial nitric oxide synthase activity and/or nitric 
oxide bioavailability103.  Moreover, a cross-sectional study examining the links between 
sC5-9 and C5a products showed strong associations among these complement 
components and endothelial dysfunction 104. Complement has also been shown to induce 
inducible nitric oxide and reactive oxygen species, two mediators, when produced in 
close proximity, that can form peroxynitrite and lead to eNOS uncoupling105 106. 
Collectively, these studies support a role for complement deregulation in vascular 
damage and atherosclerosis, especially in patients with autoimmunity. Nonetheless, exact 
mechanisms of this pathophysiological impact are unknown.  
 
Longer Course of Disease  
Improvements in SLE patient longevity have not come without consequence.  
Notably, Urowitz et al. first observed that cardiovascular-related deaths were more 
prevalent among premenopausal SLE women five years after diagnosis38.  Likewise, 
others have shown that older patients with a longer duration of disease have a higher 
prevalence of renal and ocular vascular complications.  Unsurprisingly, patients with a 




suggesting that duration of disease serves as a lupus-specific risk factor for 
cardiovascular complications 107, 108. However, studies are missing regarding the impact 
of disease duration on endothelial function.   
In summary, this group of risk factors for ED and atherosclerosis in SLE patients 
are important to note.  Nevertheless, inconsistent findings throughout the literature 
suggest these risk factors only partially account for the advanced atherosclerotic 
phenotype observed in SLE patients. In fact, recent studies provide a strong rationale for 
studying mechanisms whereby type I interferons may induce ED in SLE patients. 
Collectively, these risk are thought to contribute to the development of 
accelerated atherosclerosis in SLE.  Further, there may be crosstalk between pathways 










































Figure 2-1. Accelerated atherosclerosis in SLE patients arises from a complex 
interplay between common risk, shared factors, and SLE-specific risk including 





























Endothelial Dysfunction  
 
Endothelial Cell Homeostasis 
 
The endothelium lining the blood vessels has a dynamic role in maintaining vascular 
homeostasis.  Homeostasis is maintained under quiescent conditions by the release of 
paracrine and autocrine signaling between the blood and tissue.  Vasodilation, trafficking 
of hematopoietic cells, and unperturbed flow allow for optimal vascular function109.  
Endothelial cell perturbations arise in the presence of pathogenic factors including 
cytokines, chemokines, shear stress, and conventional cardiovascular disease risk factors 
leading to endothelial cell activation.  Endothelial cells are part of the innate host defense 
system, releasing chemokines and expressing proteins that may promote injury resolution.  
Howbeit, constant insult leads to deleterious effects on genes and endothelial cell 
responses that promote “endothelial dysfunction.”    
 
Endothelial responses in chronic inflammation 
Vascular architecture is quite heterogeneous where large diameter vessels including 
arteries and veins, are responsible for regulating blood flow.  In contrast, small vessels 
like capillaries and arterioles modulate blood pressure. Moreover, microvascular 
functions within the body are quite organ specific.  There are three main types of blood 
capillaries, which include continuous, fenestrated, and sinusoidal.  Continuous capillaries 





monolayer, allowing only ions and small gas molecules to diffuse across the layer110.    
Porous endothelial cells lining the walls of fenestrated capillaries found in the glomerulus 
contains a diaphragm made up of glycocalyx that allows passing of small protein and 
molecules  to pass through these cells111.  On the other hand, sinusoidal capillaries have 
an incomplete basement membrane, which makes this type of vessel quite leaky allowing 
for clearance of larger proteins and cells.  Sinusoidal capillaries are found mainly in 
lymph, bone marrow, adrenal tissues, and the liver112.    
Although heterogeneity persists throughout the vasculature, inflammatory insults 
elicit similar endothelial cell responses.  Upon injury or infection, antigen presenting cells 
such as macrophages and dendritic cells, process the foreign antigen and release 
chemokines and cytokines that recruit more immune cells to the site of inflammation113.  
Activation of the endothelium by cytokines such as tumor necrosis factor –α  (TNF-α) 
yields exocytosis of stored coagulation factors such as von Willebrand Factor  (vWF)114, 
115.  TNF-α also promotes endothelial selectin and immunoglobulin superfamily receptor 
expression on the endothelial cell surface116.  Macrophages and endothelial cells feed the 
inflammatory response by releasing the chemokine  CXCL8, also known as interleukin-8  
(IL-8)117.  IL-8 serves as a guide for neutrophils and monocytes expressing the IL-8 
receptor  (CXCR1) , promoting their migration into the sub endothelial space118.  
Immune cells have specific carbohydrate chains, cytokine and/or chemokine receptors, 
as well as integrin which consist of alpha and beta domains that aid in the process of 
diapedesis which consists of four stages including rolling, adhesion, binding, and 





such as monocyte chemoattractant protein 1 and IL-1β, and TNF-α119.  Upon reaching the 
site of inflammation, neutrophils slow down and adhere to the inflamed endothelium 
through interactions between CD18, a carbohydrate ligand, and P-and E-selectin120.  
Moreover, macrophage derived cytokines enhance neutrophil β2 integrin affinity to their 
respective receptors.  β2 integrin involved in neutrophil cellular adhesion include LFA-1, 
VLA4, and α4β7 which bind ICAM-1, VCAM-1, and MADCAM-1, respectively. IL-8 
transforms the inflammatory microenvironment to promote massive leukocyte infiltration 
to the site of infection. Finally, diapedesis is facilitated via endothelial cell permeability 
and  interactions with G-protein coupled receptors on the endothelial cell surface121. 
A similar process is observed in monocyte extravasation as well.  Briefly, 
tetrasaccharide sialyl-LewisX carbohydrate molecules are expressed on the cell surface of 
monocytes recruited to the site of inflammation by chemokines such as monocyte 
chemoattractant protein-1.  Further up regulation of ICAM-1 and VCAM-1 allows for 
secured endothelium-leukocyte interactions. Both monocytes and neutrophils play an 
integral role in the development of atherosclerosis and endothelial dysfunction through 
promoting unresolved insult to the endothelium.  
In vitro and in vivo studies provide insight on endothelial cell responses to 
inflammatory mediators that may perturb normal blood flow and endothelial cell health.  
Vascular NO serves multiple functions as a vasodilator, immune system modulator, and 
anti-atherogenic molecule. NO dilates blood vessels by stimulating the heme group of 
soluble guanylyl cyclase  (sGC), leading to cyclic guanosine monophosphate  (cGMP) 





factor kappa B  (NF-κB) activation site and prevents expression of VCAM-1 on the 
endothelial cell surface123.  Similarly, NO reduces specificity protein-1  (Sp1) and 
activator protein 1  (AP-1) binding to the ICAM-1 promoter region124. NO can also 
inhibit leukocyte adhesion molecule CD11/CD18 expression and interfere with the 
leukocyte CD11/CD18 binding to the endothelial cell surface125.  
In preventing atherogenesis, most of its effects are mediated through cyclic guanosine 
monophosphate   (cGMP) derived from activation of the “NO receptor” soluble guanylate 
cyclase  (sGC) 126.  sGC contains an NO heme binding site that changes confirmation 
upon NO interactions.   cGMP serves as a second messenger molecule which activates 
protein kinase G  (PKG)127.  PKG isozymes are serine/threonine kinases.  PKG is 
expressed highly in smooth muscle cells and platelets where its activation leads to 
inhibition of intracellular calcium  (Ca2+ ) flux and subsequent loss of myosin light chain 
kinase  (MLCK) activation resulting in blood vessel relaxation128. 
Early studies showed that in platelets, prevention of Ca2+ impairs integrin mediated 
conformational changes in GPIIb/IIIa fibrinogen receptors responsible for platelet 
aggregation129, 130.  While recent findings suggest that NO inhibits platelet aggregation 
under pathophysiologic conditions by blocking adenosine diphosphate  (ADP) and 
collagen conformational changes in platelet gpIIb/IIIa receptors131.  
Furthermore, NO prevents smooth muscle proliferation, which is important for 
fibrous cap formation in atheroma. NO reacts with alkoxyl radicals to prevent oxidation 
of lipids and LDL typically engulfed by macrophages that morph into foam cells, forming 





It is clear that release of endothelium-derived NO under normal and pathophysiologic 
conditions is protective against atherogenesis and vascular endothelial dysfunction .  
However, NO produced in excess can be detrimental to the endothelial milieu and may 
perpetuate the atherogenic process.133  Thus, tight regulation of eNOS is necessary for the 
maintenance of vascular homeostasis.  
`   
Endothelial Nitric Oxide Synthase Regulation Under Normal and 
Pathophysiologic Conditions 
Endothelial nitric oxide synthase  (eNOS) is a member of the nitric oxide synthase 
family and is encoded by the NOS3 gene present on chromosome 7 of the human 
genome134.  The three members of the NOS family include neuronal  (NOS1/nNOS), 
inducible  (NOS2/iNOS), and endothelial  (NOS3/eNOS).  Neuronal NOS is one of two 
constitutively expressed NOS isozymes and is located on chromosome 12.  nNOS is 
found in neuronal cells, skeletal muscle, and cardiac muscle and has been implicated as a 
critical player in neurotransmission.  Inducible NOS, found on chromosome 17, is not 
active in resting cells but can be induced upon stimulation by proinflammatory cytokines, 
LPS, and infectious pathogens. As such, iNOS is essential for host innate immune 
mechanisms that prevent infection.  eNOS is expressed in the endothelium and cardiac 
myocytes where its primary role is the maintenance of vascular health.  
All NOS isoforms consists of homodimers with uniquely structured oxidase and 
reductase domains.  The reductase domain of one monomer consists of binding sites for 





supplies the prosthetic heme group and binding sites for  (6R) 5,6,7,8-tetrahydrobiopterin  
(BH4), molecular oxygen, and the substrate L-arginine135, 136. Upon enzyme activation, 
electrons derived from NADPH are passed to flavins and then transferred to the heme 
group in the oxygenase domain. The heme iron then binds dimeric oxygen, leading to the 
stepwise production of NO.  In all cases, NO synthesis occurs with two enzyme cycles.  
During the first cycle, L-arginine hydroxylation to Nω-hydroxy-L-arginine occurs.  In the 
final step, oxidation from Nω-hydroxy-L-arginine to L-citrulline occurs, and NO is 
synthesized  137, 138.  
Although catalysis of L-arginine leads to NO production, the NOS enzymes have 
divergent activation mechanisms.  Activation of nNOS and eNOS can be dependent or 
independent of increases in intracellular Ca2+ concentrations that support the binding of 
calmodulin139, 140.  On the other hand, iNOS immunoactivation  (i.e. LPS, IFNγ) does not 
require elevated Ca2+ due to iNOS’s high affinity for calmodulin in resting cells141, 142, 143.  
Moreover, the duration and concentration of NO produced varies depending upon the 
enzyme isoform, stimulus, and microenvironment 144.       
The kinetic determinants for molecular targets are the contingent rate of production 
and consumption of NO, diffusion distance, and interactions with reactive nitrogen 
species 145.    NO production rates depend on substrate and cofactor availability in 
addition to the rate of electron transfer from the reductase to the oxygenase domains.  
Low doses of NO  (<1-30nM), generally produced by eNOS, target the conversion of 
soluble guanylyl cyclase  (sGC) to cyclic guanosine monophosphate  (cGMP) and 





anti-inflammatory effects.  Moreover, the accumulation of NO between 30-60nM 
promotes phosphorylation of Akt.  At levels between 100-200nM, the direct effect of NO 
on HIF-1α stabilization promotes cell proliferation and angiogenesis while preventing 
tissue damage. Inducible NOS found in macrophages generally produces NO at the 
400nM range, leading to phosphorylation of p53.  Due to the scope of this dissertation, 
the remainder of the discussion on NOS enzymes will be solely focused on eNOS and 
endothelial-derived NO signaling pathways. 
Pathobiology in eNOS Deficient Mice 
 
Pharmacologic inhibition of NOS isoforms limits the ability to decipher between 
the impacts of specific NOS isoform deficiencies as many antagonists are non-specific.  
Thus, genetic manipulation of NOS isoforms is used to further understand the role of 
each isoform independently.  eNOS knockout mice display hypertension, deficient 
vasorelaxing activity146, and heart failure147. They also have abnormal aortic valve 
function and altered wound healing capacity148, resulting from deficient response to 
vascular endothelial growth factor  (VEGF)-stimulated angiogenesis149 Moreover, they 
are more prone to insulin resistance and moderate albuminuria, as well as developing a 
phenotype mimicking human metabolic syndrome 150.  However, eNOS deficient animals 
do not spontaneously develop atherosclerosis due to NO synthesis by nNOS and iNOS151.  
Thus, genetic manipulation of atherogenic pathways or changes in the environment  (i.e., 





For instance, ApoE/eNOS double knockout animals on a high fat diet show 
enhanced atherosclerotic lesion development and more pronounced coronary artery 
disease, left ventricular dysfunction, and ineffective pharmacological blood pressure 
control 152.  Moreover, LDLr-/- animals have reduced eNOS expression and 
phosphorylation, likely due to hyperactivation of the oxidized low density lipoprotein  
(oxLDL)-LOX-1 pathway, which silences eNOS expression and NO production153.  
Diabetic vascular complications are partially attributed to chronic suppression of 
eNOS pathways.   Genetic disruption of the eNOS gene predisposes streptozotocin  
(STZ) diabetic mice to accelerated retinopathy and nephropathy154.   Moreover, diabetic 
mice with genetically ablated eNOS present with hypertension, enhanced endothelial cell 
proliferation, vascular endothelial growth factor production within the glomerular and 
peritubular capillaries, and overall renal incompetency155.  
Recent studies from our lab showed that in 156MRL/lpr mice developing 
spontaneous lupus, lack of NOS 3 resulted in increased aortic lipid deposition157 and 
increases in clinically significant crescentic and necrotic glomerulonephritis156 .  These 
studies demonstrated that eNOS is a significant regulator of oxidative stress, which can in 
turn signal inflammation.   
 
Physiological stress exacerbates renal injury in these animals158. In addition, diabetic 
NOS 3  (eNOS) -/- mice develop accelerated retinopathy159, more pronounced glomerular 










eNOS gene polymorphisms identified within the human genome associate with an 
increased propensity toward endothelial dysfunction and cardiovascular disease 
162Furthermore, eNOS polymorphisms in exon 7  (894 GT) and in the promoter region  
(T-786C) predispose patients to enhanced carotid intima-media thickness and 
functional changes in the endothelium163.  A study examining the GluAsp or AspAsp 
genotype of the Glu298Asp eNOS polymorphism in 337 diabetic patients showed a 
significant association with ischemic heart disease164.  Subsequently, a study of 8 variants 
of the eNOS gene in Caucasian diabetic patients revealed that -786T>C, Glu298Asp and 
an intron 8 polymorphism are possibly involved in the atherosclerotic pathway 165. 
Several studies have assessed the relationship between common eNOS variants and 
risk or severity of SLE.  The eNOS gene intron 4a/b VNTR polymorphism, consisting of 
27 base-pair tandem repeats, is a risk factor for glomerulonephritis in SLE patients and 
implies rheumatoid arthritis  (RA) susceptibility166 167.   In an evaluation of 225 northern 
Chinese lupus nephritis patients, logistic regression analysis revealed a strong association 
between the 894T allele and lupus nephropathy but not genotype frequency of the -786C 
allele 168.  In a meta-analysis examining 8 independent studies to that investigate the role 





showed a moderate association with SLE disease risk167.   Nevertheless, studies 
examining the link between endothelial dysfunction and eNOS polymorphisms in SLE 
patients have not been reported, suggesting that changes in eNOS function in SLE are not 
solely due to germ line mutations.  This raises the possibility that pro-inflammatory 
mediators  leading to altered gene expression or enzyme function are responsible for loss 
of endothelial function in lupus.  
Thus, understanding mechanisms of eNOS gene regulation, expression, and 
enzymatic activation may provide insight on therapeutic targets important for the 
prevention of vascular abnormalities such as endothelial dysfunction.  
 
 
Regulation of Endothelial Nitric Oxide Synthase Expression 
Transcription, translation, and post-translational modifications regulate eNOS 
expression within cells.  Although there is some controversy as to whether impaired 
transcription negatively impacts NO output, it is important to note that various factors 
play a role in the bioavailability of NO. 
Modulation of the eNOS Promoter 
The eNOS promoter region contains several binding motifs for AP1 complex, Sp1/2, 
NF-κB, KLF2, IL-6, p53, PEA3, YY1, shear stress, heavy metal, acute phase response-, 
cAMP response-, retinoblastoma control, interferon γ response, sterol-regulatory cis-
elements, and GATA.  Cloning experiments coupled with site specific mutations revealed 





transcription. Specific mutation of GATA sites within the eNOS promoter further 
revealed that GATA mediated eNOS promoter activation largely influences gene 
transcription169.  Phorbol-12-myristate-13-acetate  (PMA) induces PKC-α/Δ mediated 
eNOS promoter activity in bovine aortic endothelial cells170.  Laminar shear stress 
modulates eNOS mRNA expression and promoter activity by inducing transient nuclear 
translocation of the p50 NF-κB subunit to the NF-1/SSRE eNOS promoter region.  Yet, 
NO negatively regulates NF-κB mediated transcription by nitrosylating the p50171, 172.  
Unsurprisingly, controversies exist surrounding NF-κB involvement in endothelial 
dysfunction173.  
Growth factors also regulate eNOS promoter activity. Fibroblast growth factor 2 
promotes AP-1 binding to the eNOS promoter through an ERK1/2Jun B mediated 
pathway174.  Vascular endothelial growth factor  (VEGF) induces eNOS gene expression 
possibly through an ERK1/2 dependent pathway175.  Other growth factors involved in 
eNOS gene expression include transforming growth factor β  (TGFβ) and epidermal 
growth factor  (EGF)176. 
Cytokines and pro-atherogenic inflammatory mediators such as TNF-α, C-reactive 
protein, and oxidized LDL can impair eNOS gene expression.  It is well established that 
TNF-α has pleiotropic effects on eNOS gene expression.  Studies have shown that TNF-α 
suppresses eNOS promoter activity by promoting GATA-4 binding to the  (-231) site and 
Sp3 binding to the  (-370) CACCCC site in pulmonary micro vessel endothelial cells177.  
Of conventional cardiovascular disease risk factors, hyperglycemia was shown to impair 





subsequent activation of AP-1 in human aortic endothelial cells178.  Moreover, C-reactive 
protein reduces eNOS gene expression, leading to diminished activity and loss of eNOS 
derived NO production 179,  (Figure 2-2).  
Gaseous molecules also regulate eNOS transcription in physiologic and 
pathophysiological conditions.  Hydrogen peroxide  (H2O2)  enhances eNOS transcription 
and mRNA half-life in response to laminar shear stress180 Yet, under pathophysiologic 
conditions, up regulation of eNOS by H2O2 derived from NADPH oxidase 4  (NOX4) 
activity may result from eNOS uncoupling, yielding enhanced non-nitrous reactive 
oxygen species production and diminished endothelial function181 182. Thus, controversy 
exists as to whether up regulation or diminished expression of eNOS alone is sufficient to 
influence NO production.   
Following transcription from DNA to RNA, RNA is further processed into messenger 
RNA  (mRNA), which includes splicing and protein synthesis. Studies have shown that 
TNFα induces post-transcriptional modifications in multiple ways.  TNFα causes mRNA 
instability through up regulation microRNA 155  (miR155)183. This microRNA binds to 
the 3’UTR region of eNOS mRNA and causes destabilization.  This is an NF-kB-
mediated mechanism whereby TNFα causes nuclear translocation of the p65 subunit and 
subsequent up regulation of microRNA 155. On the other hand, miR155 transfection in 
endothelial cells lead to diminished NFkB mediated adhesion molecule expression 
possibly through diminished p65 activation.  These studies suggest that miR155 may play 
a dual role in regulating inflammatory and anti-inflammatory responses on the pro-





on translation of eNOS, eNOS activity is regulated by the availability of enzymatic co-












































Figure 2-2. Cis-acting elements in the human NOS3 promoter.  External 
factors such as shear stress, hyperglycemia, and fibroblast growth factor-2 are able 













                                                        
1  This figure was adapted from 185. Searles CD. Transcriptional and 
posttranscriptional regulation of endothelial nitric oxide synthase expression. Am J 






Post-transcriptional regulation of eNOS Activity 
The Importance eNOS localization on eNOS activity 
eNOS activity is highly contingent upon its cellular location. Previous studies 
demonstrated that N-co-myristoylation at Gly2 in addition to post-translational Cys15/26 
palmitoylation target eNOS to specific cellular membranes186, 187.  In endothelial cells 
following palmitoylation, eNOS is trafficked to the plasmalemmal caveolae, where it 
binds to the major coat protein of the caveolae, caveolin-1188. The caveolae are a 
specialized subset of lipid rafts enriched in cholesterol, glycosphingolipids, 
sphingomyelin, and lipid-anchored membrane proteins189.   
Caveolin-1 is comprised of approximately 82-101 amino acids and directly interacts 
with the oxygenase domain of eNOS in its inactive state 190. In vivo and in vitro 
experiments support a role for caveolin-1 in the direct steric inhibition of calmodulin  
(CaM) binding to the CaM binding site located within the oxygenase domain of eNOS191, 
192, 193, 194. However, upon increases in intracellular Ca2+, the Ca2+/CaM interaction leads 
to CaM binding, dissociation from Cav-1, and activation of the enzyme.  Other studies 
have shown that enhanced Ca2+ promotes cycling of eNOS off the plasma membrane to 
the Golgi apparatus, further promoting NO production195.  Still, controversy exists 
regarding the relationship between eNOS location and optimal NO production.  
Interestingly, evidence suggests that location-specific activation of eNOS depends on the 







Influence of Regulatory Proteins on eNOS activity 
In addition to Cav-1, other proteins associated with eNOS impact the enzyme’s 
activity.  NOSIP and NOSTRIN are novel proteins that interact with eNOS to inhibit its 
activity.  NOSIP is a C-terminal domain binding protein that has a direct impact on eNOS 
trafficking from the plasma membrane to intracellular compartments196.  On the other 
hand, NOSTRIN-eNOS interactions result in trafficking from the plasma membrane and 
Golgi apparatus to cytosolic compartments within the cell197. Although little is known 
about the effects of inflammation on these proteins, NOSTRIN and NOSIP are 
upregulated in pathophysiological conditions198 Thus, enhanced expression of these 
proteins may partially contribute to the loss of NO production under pathogenic 
conditions.   
Heat shock protein 90   (HSP-90) is a molecular chaperone protein required for 
proper folding, conformational maturity, and subsequent activation of eNOS. HSP-90 
also plays a crucial role in eNOS dimerization199.  HSP90 plays a protective role in 
ischemia/reperfusion kidney injury through modulation of eNOS function200.   
 
The Importance of Co-Factors in eNOS Activation 
The literature suggests a causal role for BH4   deficiency in endothelial 
dysfunction.  BH4 is an eNOS cofactor responsible for maintaining enzyme coupling.  
The rate-limiting step in de novo BH4 synthesis is GTP cyclohydrolase  (GTPCH) 201.  
Although the exact role of BH4 in eNOS enzymatic activity is not fully known, BH4 is 





studies suggest that, in the absence of BH4, endothelial dysfunction and cardiovascular 
complications are exacerbated.  Several pathophysiological mediators impact BH4 
availability, including peroxynitrite and other reactive oxygen intermediates.  
Peroxynitrite, produced from the reaction of NO and O2-, creating ONOO−, causes 
reduction of BH4 to BH2. With loss of BH4, eNOS uncouples and instead of producing 
NO, it produces superoxide. In addition, vasoconstrictors, such as angiotensin II reduce 
BH4 levels in the endothelium by impairing activation of BH4 salvage enzyme 
dihydrofolate reductase  (DHFR) )202.  Finally, depletion of eNOS substrate L-arginine 
occurs under pathophysiological conditions. 
L-arginine is an essential amino acid and serves as a substrate for eNOS-mediated 
NO production by maintaining eNOS dimerization and coupling.   L-arginine is 
synthesized by argininosuccinate synthetase  (ASS) and argininosuccunate lyase  (ASL) 
from citrulline 203.  Endothelial cells express arginases that compete with eNOS for L-
arginine.  Arginase II appears to be the most dominant isozyme expressed in the 
endothelium.  Isolated carvernosal tissue from non-diabetic and diabetic patients with 
erectile dysfunction revealed an increase in arginase II levels and reductions in nitric 
oxide production204. Moreover, genetic ablation of arginase II in a streptozotocin induced 
diabetic mouse model restored corpora cavernosal relaxation205.  The expression and 
activity of arginase II were shown to be elevated in placental vessels from women with 
intrauterine growth restriction complications, while eNOS protein expression was 
reduced206 . Similarly, arginase up regulation in aged aortic mice coincided with 





uncoupling207. Further supporting these studies was the finding that arginase inhibition 
restored endothelial dependent vasorelaxation in response to acetylcholine, eNOS 
recoupling, and subsequently reduced ROS levels in aged rats208.  Thus, depletion of L-
arginine resulting from excessive arginase activity could explain loss of NO 
bioavailability and eNOS uncoupling that perpetuate endothelial dysfunction.  Studies 
showing enhanced arginase II expression in SLE are missing.   
The therapeutic effects of L-arginine supplementation have been well documented in 
both animal and humans studies of endothelial dysfunction.  L-arginine supplementation 
in Type I diabetic patients significantly improved basal lower limb blood flow209.  
Moreover, in patients with coronary artery disease, L-arginine was shown to improve 
insulin sensitivity and cyclic guanosine monophosphate   (cGMP) levels 210.  Thus, both 
L-arginine deficiency and loss of BH4 may contribute to deregulated eNOS coupling and 
activity, leading to enhanced production of superoxide and loss of NO.   
 
Regulation of eNOS Activity via  Ca2+ Flux and Phosphorylation 
Constitutively expressed eNOS cycles between active and inactive states depending 
upon intracellular calcium levels within the cell.  eNOS is activated via Ca2+ dependent 
and independent pathways.  Intracellular calcium flux leads to calmodulin binding and a 
conformational change, enhancing electron transfer between domains.  On the other hand, 
phosphorylation of the eNOS at Ser1177 can lead to enhanced CaM binding as well as 
electron flux from the reductase to oxygenase domains. Therefore, Ca2+ independent 





triggered by specific growth factors, cytokines, and biochemical mediators.  As such, 
localization of eNOS within the cell limits the rate of enzymatic activity and NO 
production.  
Indeed, eNOS phosphorylation plays a critical role in the activation of the enzyme.  
Phosphorylation sites persist throughout the reductase and oxygenase domains.  Serine 
residues include Ser1177, Ser116, Ser614, and Ser633.  However, phosphorylation at the 
Ser1177 site controls the bulk of the phospho-eNOS activation  (Figure 2-3). 
Extensive research suggests that shear stress211, VEGF212, bradykinin213, and 
insulin214 induce phosphorylation at the Ser1177 site in humans and Ser1179 in bovine and 
mice.  Ser1177 phosphorylation induces a conformational change in the auto inhibitory 
loop located in the C-terminus, which promotes the flow of electrons from the reductase 
to oxygenase domain.  Conversely, trafficking of eNOS to the plasma membrane is 
required for adequate phosphorylation, as loss of palmitoylation and myristoylation 
impedes these processes 215, 216.  
A number of kinases phosphorylate eNOS at the Ser1177 site, including Akt, AMPK, 
CAMKII, PKA, and PKG.  However, which kinase is active depends heavily upon the 
stimulus as well as the microenvironment of the cell.  For instance, upon extracellular 
insulin binding to the insulin receptor tyrosine kinase  (IR), recruitment and 
phosphorylation of insulin receptor substrate 1  (IRS-1) persists 217.  This substrate 
encompasses multiple binding sites whereby co-signaling partners bind to induce 
downstream signaling to the phosphatidylinositol  (PI) 3-kinase  (PI-3K) / protein kinase 





eNOS at the phosphor-Ser1177 site.  Akt is also activated by VEGF, Bradykinin, estrogen, 
and shear stress in a similar manner. Shear stress, histamine, atorvastatin, adiponectin, 
and thrombin induce AMP-activated protein kinase  (AMPK)-mediated phosphorylation 
of eNOS at the Ser1177 sites; while calmodulin kinase II (CaMKII)-mediated 
phosphorylation can be induced by bradykinin 218.  
Other studies examining the impact of Ser633 increase eNOS activity to levels 
comparable to Ser1177 219, 220.  In addition, Ser614 appears to have a more functional role of 
stabilizing eNOS in earlier stages of activation. Yet, it appears to be a minor factor in NO 
production.  
Conversely, the threonine495 amino acid residue  (Thr495) is constitutively 
phosphorylated by protein kinase C, an enzyme regulated by diacylglycerol, Ca2+, and 
phospholipids such as phosphatidylserine 221.  Phosphorylation at this site impairs 
electron flux from the reductase to the oxygenase domain by reducing Ca2+/CaM binding.  
Conversely, additional studies have shown that total loss of Thr495 results in eNOS 
uncoupling, suggesting that steric conformation warranted by modifications here are 
essential for proper enzymatic function.  Moreover, phosphorylation at Ser116 impairs 
eNOS activity and NO production.  Further studies are needed to determine the impact of 






Various factors promote or impair eNOS activation.  Importantly, some eNOS 
agonists have the dual-role of enhancing pSer1177/1179 while inducing reciprocal 
dephosphorylation of pThr495/497, shifting the enzyme to an active state.  Transient 
increases in intracellular Ca2+ are also regulated by specific eNOS agonists. However, the 
predominant action of biochemical factors regulating eNOS is through kinase activation 
or protein-protein interactions.    
Bradykinin  (BK) is a well-known regulator of blood pressure control that transiently 
induces PI3K/Akt mediated phosphorylation at the eNOS-serine1179 site, while reducing 
Thr497 in bovine aortic endothelial cells222.    Further, BK-mediated increases in Ca2+ lead 
to activation of CaM-dependent kinase II  (CaMKII), which phosphorylates at the ser1177 
site in porcine aortic endothelial cells213.  It should be noted that BK was shown to impair 
eNOS activation in bovine aortic endothelial cells, likely through activation of the ERK 
pathway. Nevertheless, the phosphorylation site is unclear.  Other mechanisms of BK 
mediated inhibition include B2 receptor allosteric inhibition in a time and concentration 
dependent manner  
Insulin was initially identified as a stimulus for endothelial-derived NO production in 
1994. Steinberg, et al. examined intrafemoral artery dilation in response to metacholine 
chloride or sodium nitroprusside in patients who received a saline infusion or 
hyperinsulinemic clamp created to double the rate of blood flow99.  This pioneer study 
led others to investigate mechanisms whereby insulin induces eNOS activation and NO 





mediated phosphorylation of Ser1177/1179 in a Ca2+ independent manner223.  While the 
insulin receptor negatively regulates eNOS activity by promoting caveolin-1 Tyr14 
phosphorylation224.  Moreover, insulin induces translocation of the eNOS/Cav-1 complex 
to the perinuclear region to the plasma membrane in cultured bovine aortic endothelial 
cells in a PI-3K dependent manner and contingent upon increases in palmitoylation225. 
Recent studies highlight the role IL-6 in insulin-resistance suggesting that inflammatory 
mediators are important in modulating the insulin-eNOS axis61 Consequently, insulin-
mediated signaling pathways are impaired by protein kinase C-β in obesity-associated 
insulin resistance. 
 
eNOS Negative Feedback Inhibition 
Caveolin-1 phosphorylation enhances Cav-1/eNOS interaction to prevent further 
production of NO Moreover, NO activates NF-kB, a transcription factor which directly 
binds the promoter region of the NOS3 gene to prevent transcription of the enzyme226.  
While cGMP impairs calcium mediated activation of eNOS via prevention of 
intracellular Ca2+ flux 227.  Moreover, studies in cardiomyocytes revealed that NO 
modulates L-arginine transport through impairing cationic amino acid transporter 
activity228 . 
In conclusion, Endothelial nitric oxide synthase  (eNOS) is a key regulator of 
homeostatic mechanisms within the cardiovascular system.   eNOS is regulated by 
multiple mechanisms including transcription, post-transcriptional, and post-translational 





or protein-protein interactions may impede processes leading to NO synthesis.  
Furthermore, recent evidence suggests a role for transcriptional and post-transcriptional 
modifications that may be essential for NO bioavailability as well. Understanding 
regulation of eNOS in physiologic and pathophysiologic conditions is essential for the 
development of therapies that improve endothelial dysfunction and cardiovascular 
disease highly susceptible patient populations. Recent studies suggest that Type I 
interferons, specifically interferon alpha, may be a reasonable therapeutic target for 
preventing endothelial dysfunction in SLE. Still, its effects on eNOS and NO production 






















































Figure 2-3. Endothelial nitric oxide synthase is activated by calcium dependent and 

































Figure 2-4. Pathophysiologic conditions negatively modulate nitric oxide 
production through various pathways.  Oxidative stress, for example, is known 
to induce eNOS uncoupling and subsequent loss in NO.  While, inflammatory 
cytokines often impair eNOS activation and expression leading to deficient eNOS 




















Endothelial Dysfunction and Type I Interferons in SLE 
 
Type I interferons accelerate atherosclerosis in both mice and humans. 
Atherosclerotic plaque area, triglyceride levels, and serum cholesterol levels were 
increased following low dose IFN-α treatment in LDLr-/- mice, a phenomenon possibly 
due to enhanced lipolysis229.  Moreover, NZM  (lupus prone) Apoe-/- Ifnar-/- mice have 
improved aortic ring relaxation, less platelet aggregation, decreased T lymphocyte and 
macrophage plaque infiltration, and declines in thrombosis compared to animals with the 
receptor intact230.  Surprisingly, rat aortic rings treated with high dose IFN-α show 
reductions in relaxation, which may be an indication of impairments in endothelial cell 
function231. These combined studies show effects of IFN-α on multiple stages of 
atherosclerosis and vascular complications in mouse models, thereby providing further 
evidence for type I IFN-specific mechanisms involved in the increased incidence of CVD.   
As is true of Framingham risk factors and vasodilation, IFN-α also alters levels of 
circulating endothelial progenitor cell  (cEPCs), an additional marker of ED. Moreover, 
like patients with Framingham risk factors, SLE patients have reduced levels of cEPCs, 
leading to loss of vascular repair and potentiated vessel damage232.   
Previous studies indicate that eNOS-derived NO regulates cEPC mobilization and 
functions in response to VEGF233, shear stress, estrogen234, and exercise235.  In support of 
these findings, studies in mice show that VEGF-mediated NO production leads to the 
release of EPCs from bone marrow following enhanced matrix metalloproteinase-9  





IFNs associate with attenuated mobilization and function of EPCs in SLE patients. 
Moreover, SLE EPCs mature abnormally and display reductions in VEGF and human 
growth factor gene expression in vitro. In addition, these abnormalities are restored with 
the addition of anti-IFN-α neutralizing monoclonal antibodies237.  Lupus patients with 
significant reductions in peripheral blood EPCs display increases in peripheral blood 
mononuclear cell  (PBMC) expression of MX1, a reporter gene for Type I IFN. Patients 
with elevated MX1 levels also exhibit declines in vascular reactivity and endothelial 
dysfunction as measured by peripheral arterial plethysmography238.  Studies associating a 
type I IFN signature with endothelial dysfunction are limited in SLE patients; however, 
examples of this phenomenon are demonstrated in other non-autoimmune populations, 
such as those with hepatitis C.   
Early studies in chronic hepatitis C patients demonstrate a role for IFN-α in 
exacerbating cardiovascular complications and endothelial dysfunction.  Compared to 
those not treated with IFN, patients receiving IFN-α 2b therapy had increased incidence 
of atrioventricular block239, myocardial disease240, ischemic heart disease241 and severe 
sinus bradycardia242 in the absence of traditional cardiovascular risk factors.  Accordingly, 
upon discontinuation of IFN treatment, patients improved, suggesting that IFN-α 
treatment effects were transient rather than permanent 243.   
During treatment, Hepatitis C patients demonstrated impaired flow mediated 
vasodilation244 in addition to increases in VCAM-1, monocyte chemotactic protein-1  





serum levels of Type I IFN directly mitigate proper endothelial function and counteract 
pathways normally regulated by NO.  Still, controversy remains about whether or not 
these effects of IFN-α in therapeutic settings are causes for concern, as some studies 
suggest only modest effects of IFN-α on cardiac toxicity243, 246. 
Furthermore, this elevation in Type I interferons may play a role in the suppression of 
eNOS activity expression within the vasculature in SLE patients, making them more 
susceptible to vascular pathologies.  To understand the effects that Type I interferons may 
have on eNOS function, the role of eNOS in physiologic and pathophysiologic conditions 
must be elucidated. 
 
Endothelial Nitric Oxide Synthase and Type I Interferons 
It is now understood that inflammatory production of Type I IFNs and their 
therapeutic use may cause changes in vascular endothelial function. Thus, a focus on the 
mechanisms whereby IFN-α may alter eNOS and NO production is justified.  The 
question therefore arises as to how and if Type I interferons can affect eNOS function 
and NO production. To date, no studies have published the impact of IFN-α on eNOS 
enzymatic function and NO production.  However, type I IFNs have been reported to 
have direct and indirect effects on eNOS specific transcription factors, co-factors 
important for eNOS regulation, kinases and phosphatases important for enzyme 





Modulation of transcription factor binding to the eNOS promoter is affected by 
humoral and physical factors in  (patho) physiologic states. Regulatory transcription 
factors were shown to include the followings: Sp1/3 and AP-1 and 2-transcription factors. 
Reductions in the binding of Sp1/3-containing complexes with the eNOS promoter leads 
to declines in eNOS expression in TNF-a–treated bovine aortic endothelial cells.20 
Like TNF-α, IFN-α reduces Sp1/3 activation, leading to decreases in VEGF 
transcript levels in pancreatic carcinomas247. IFN-α also alters Sp1 binding in primary 
human hepatocytes, leading to decreased c-Met mediated cell proliferation248.  eNOS 
promoter activity is also dependent upon AP-1 binding.  Previous studies showed that 
porcine aortic endothelial cell  (PAEC) exposure to hydrogen peroxide  (H2O2) lead to 
declines in eNOS expression as a result of impaired AP-1 eNOS promoter binding249. 
Likewise, transfection of IFN-α adenovirus into 253J BV cells blocks AP-1 activation in 
addition to other nuclear pro-angiogenic signals250.  Thus, IFN-α may reduce eNOS 
transcription by affecting the expression of transcription factors essential for eNOS 
promoter activation.   
eNOS is activated by phosphorylation at serine sites located within the reductase 
domain, including serine1177, serine 633, and serine 615 and dephosphorylation at serine114, 
threonine 495 and tyrosine657 251.  Phosphatase 2A  (PP2A) blunts phosphorylation of the 
enzyme at the activation sites in CRP-primed human aortic endothelial cells  (HAECs)73. 
PP2A activation occurs upon stimulation by intracellular enzymes, including the IFN 





for preventing eNOS-S1177 activation, including Jun N-terminal kinase  (JNK) and 
extracellular signal regulated kinase1/2  (ERK1/2) activation253. Alternatively, it has been 
demonstrated that PKR promotes p38 activation, a kinase previously shown to 
phosphorylate eNOS-S1177 in human vascular endothelial cells in response to insulin254.  
eNOS-specific kinases are activated by extracellular stimuli like VEGF.  IFN-α, given as 
a treatment for liver cancer, suppress VEGF mRNA transcription, VEGF plasma levels, 
and micro vessel densities255.  Moreover, human umbilical vein endothelial cells  
(HUVECs) treated with IFN-α and 5-fluorouracil  (5-FU) had reduced VEGF 
transcription and secretion256.  Collectively, these studies suggest a possible role for IFN-
α induced changes in eNOS phosphorylation through down-regulation of VEGF and loss 
of kinase activation  (Figure 2-5).  
Type I Interferon and Tetrahydrobiopterin  (BH4) 
BH4 is essential for proper eNOS coupling and the flow of electrons from the 
reductase domain to L-arginine and subsequent NO production.  Proper BH4 levels are 
important for endothelial cell maintenance, where 60% of all BH4 has been identified in 
the vascular wall257, 258 Inadequate supply of BH4 during oxidative stress can lead to 
eNOS uncoupling, either through inadequate synthesis by guanosine 5’-triphosphate 
cyclohydrolase 1  (GTPCH) or oxidation of BH4 259. Although the exact effects of IFN-α 
on BH4 synthesis and oxidation remain unclear, both animal and human studies support a 





IFN-α  (105 units/kg) injections in rat amygdala and raphe areas leads to abatement of 
BH4 260. Moreover, IFN-α-treated hepatitis C subjects have low levels of BH4 and higher 
levels of its inactive oxidized form dihydrobiopterin  (BH2) 261. Thus, IFN-α may serve 
as a potential mediator of eNOS uncoupling and oxidative stress in vascular ED by 
promoting depletion of eNOS co-factors.  Collectively, these studies suggest that 





When BH4 levels are low and eNOS remains uncoupled, the enzyme can act as an 
NADPH oxidase, producing reactive oxygen species  (ROS) in excess.  Superoxide  (SO) 
scavenges NO via a direct chemical reaction that yields peroxynitrite  (ONOO-) 
production within the vascular wall.  It is important to note that peroxynitrite has multiple 
pro-atherogenic effects. First, it oxidizes the eNOS cofactor BH4 to BH3. radical.  This 
oxidation, in turn, uncouples NOS and reduces NO production, while simultaneously 
increasing SO production. Second, it causes inhibition of cellular L-arginine transport 
important for NO production 262.  Third, ONOO- stimulates release of thromboxane A2 , a 
known contributor of eNOS dysfunction 263. Fourth, ONOO-  activates the production of 
PP2A, leading to dephosphorylation of eNOS and endothelial dysfunction. Thus, ONOO- 
causes eNOS uncoupling and inactivity in addition to perpetual SO production. 
SO has multiple indirect effects on eNOS function.  For example, it oxidizes LDL to 
oxLDL.  OxLDL, in turn, binds to LOX-1 and CD36 expressed on the endothelial cell 
surface, which, upon activation, can inhibit eNOS activation. OxLDL also stimulates 
xanthine oxidase and NADPH oxidase  (NOX) to produce SO anions, which likely 
promotes eNOS deactivation. Collectively, these studies suggest that SO negatively 
impacts the endothelium by reducing availability of physiologic NO and promoting a 
continuous cycle of oxidative stress. 
Type I Interferons, Arginase, and L-arginine 
Studies examining the role of interferon on L-arginine availability are also limited.  
However, a study conducted in high-risk melanoma patients showed that pegylated IFN-





addition, IFN-α induces NO synthase 2  (iNOS) in various cell types, resulting in 
depletion of extra- and intracellular L-arginine stores 265. Thus, IFN-α mediated depletion 
of L-arginine may result in loss of NO ultimately leading to ED observed in patient 


















































Figure 2-6. IFNα may impact NOS3 transcriptional regulation. Factors 
regulated by IFN-α potentially involved in the loss of endothelial derived NO are: 
negative regulation of vascular endothelial growth factor  (VEGF) production 
important for eNOS activation; impaired activator protein-1 (AP-1) activation and 
specificity protein 1 and 3 (SP1/3) function, both responsible for  nitric oxide 

































Type I Interferons, Reactive Oxygen Species, and Endothelial Dysfunction 
Imbalances in L-arginine and other co-factors essential for proper eNOS regulation 
can lead to the phenomenon known as oxidative stress. Oxidative stress is characterized 
as an imbalance in the production of reactive oxygen species and antioxidants, leading to 
dysfunctional endothelial cells. ROS impacting endothelial cell signaling mechanisms 
include free radicals such as SO, ONOO.-  (peroxynitrite), and OH.  (hydroxyl radical), 
and non-radicals including H2O2.  Conventional risk factors including hypertension, 
diabetes mellitus, and hypercholesterolemia dramatically potentiate ROS levels in the 
vascular wall, promoting oxidative stress. 
The magnitude of oxidative stress depends on levels of oxygen free radicals   (SO) 
within the cell and the availability of antioxidants to reduce these molecules.  In addition 
to uncoupled NO synthases  (NOSs), a number of enzyme systems produce ROS in 
endothelial cells including NADPH oxidases  (NOX)266, xanthine oxidases, arachidonic-
acid metabolizing systems, the mitochondrial electron transport chain, and the 
cytochrome P450 enzyme. Conversely, three superoxide dismutase enzymes are 
important for counteracting superoxide production including copper zinc SOD, 
manganese SOD, and endothelial cell SOD.  On the other hand, H2O2 degrades in the 
presence of glutathione peroxidase and catalase. 
SO production in the endothelium is mainly derived from NOX, xanthine oxidase, 
and NOS enzymes. NOX 2 and 4 are the major producers of SO in the endothelium; 
however, other isoforms of these enzymes can be expressed by vascular smooth muscle 





availability along with endothelial function. Evidence for NOX activation in the vascular 
wall has been provided in human studies. In a clinical setting, NOX2 was shown to be 
most important in producing cytotoxic levels of ROS in insulin-resistant endothelial 
cells267. Moreover, studies in patients undergoing coronary artery bypass graft surgery 
showed NOX as the major source of ROS production resulting in ED268. In addition to 
NOX, others have shown exogenous xanthine oxidase prevents VEGF-induced NO 
production and endothelial cell survival whereas endogenous levels of NO are important 
for normal cell signaling mechanisms269. Uncoupled NOS is also a significant generator 
of SO and is reportedly involved in the pathogenesis of atherosclerosis270, 271, 272.  
Free radical reactions between SO and NO result in ONOO.- synthesis and, 
inactivation of NO. NO is not only important for blood vessel dilation and homeostasis, 
but also binds and inhibits complex IV in the electron transport chain, impairing release 
of ROS.  NO also impairs activation of NOX enzymes within the cell, thus further 
regulating ROS production.  NO also serves as a paracrine agent by modulating NOX 1 
expression in mesangial cells and regulating the activity of NOX2 via phosphorylation of 
the NOX 2 p47 subunit273.  However, an imbalance in NOX activation yields NO 
depletion and subsequent endothelial dysfunction.  IFN-α induces NADPH oxidase 
activation and SO production in endothelial cells, promoting leukocyte adhesion to rat 
vessel walls, a phenomenon abrogated by SOD and other immune modulators274. 
Moreover, IFN-α induces NADPH oxidase activation in rat liver pre-neoplasia leading to 
apoptosis. However, studies are missing showing the downstream impacts of IFN-α 






















Figure 2-7. IFNα may promote oxidative stress leading to eNOS uncoupling 
and NF-kB induction.  Nicotinamide adenine dinucleotide phosphate oxidase  
(NADPH oxidase) transcription via NF-kB and its activation were also previously 
shown to be mediated by IFN-α and, are important for superoxide  (O2.-) 
production contributing to peroxynitrite  (ONOO-) synthesis in the presence of NO. 
ONOO- has detrimental impacts on the endothelium including reduction of 
tetrahydrobiopterin  (BH4) to dihydropteridine  (BH2) resulting in eNOS 
uncoupling.  The uncoupling of eNOS disturbs oxidative balance by increasing the 
production of O2.- within the cell and, may cause cellular dysfunction owing to an 
overwhelming amount of oxidative stress. Incidentally, loss of NO yields platelet 
aggregation, monocyte chemoattractant protein-1  (MCP-1) production, vascular 
adhesion molecule-1  (VCAM-1) transcription and, intracellular adhesion 


















Endothelial dysfunction is highly prevalent among lupus patients and associates 
with multiple circulating factors including Type I interferons.  Studies in other tissues and 
disease states support a role for IFN-α in reducing transcription of eNOS, reducing post-
translational activation of eNOS, reducing eNOS cofactor availability leading to 
uncoupling, and increasing reactive oxygen production that can lead to scavenging of NO. 
However, studies regarding the role of Type I interferons in eNOS dysfunction and loss 
of NO bioavailability both directly and indirectly in lupus patients are missing.  As 
detailed here, Type I interferons may serve as novel, rational targets for study in 













































Common Methods for Chapters IV and V 
 
Patient population 
This research was conducted in accordance with the Helsinki Declaration with approval 
from the Institution Review Board at the Medical University of South Carolina.  
Specimens for this study were stored and collected from study visits that were part of a 
longitudinal observational cohort study known as the SLE Gullah Health or SLEIGH 
study initiated in 2002 by Dr. Diane Kamen. A thorough description of the study has 
previously been described275.  All patients classified as SLE meet 4 of the 11 
classification criteria as specified by the American College of Rheumatology  (ACR)7.    
Clinical Characteristics of the Study Population 
Clinical characteristics of the study populations are outlined in Table 3-1.  There 
was no significant difference between the two groups in patient age, race, or sex.  
Systolic and diastolic BP were similar as well. Lupus disease activity was assessed 
by SLE Disease activity index  (SLEDAI) scores and systemic lupus international 
collaborating clinics  (SLICC) scores which is an assessment of irreversible 




















Blood from healthy and SLE participants were collected in a sterile vacutainer blood 
collection tube and whole blood was allowed to clot at 25°C for 10 minutes.  Samples 
were centrifuged to remove the clot and remaining serum was stored at 80°C for future 
use.   
Neutrophil Isolation 
 
The Institutional Review Board at the Medical University of South Carolina approved use 
of human neutrophils and all donors provided informed consent. Neutrophils were 
isolated as previously described 276.  Briefly, 20 mls of human blood was acquired from 
healthy volunteers and cells were isolated using Lymphocyte Separation Medium  
(Cellgro, Manassas, VA, USA). The assay was validated based on forward scatter and 
side scatter using flow cytometry as shown in Figure 3-1. 
 
Endothelial Cell Culture and Serum Treatment 
 
Primary HUVECs from pooled donors were purchased from Lonza  (Walkersville, MD) 
and cultured according to the manufacturer’s instructions in 5% CO2 at 37°C.  HUVECs 
were subcultured using TryPLE Express dissociation reagent when cells were 70-80% 
confluent.  Cell growth was limited to 12 population doublings and all experiments were 





















Figure 3-1. A. Depiction of neutrophil-like subset isolated from whole blood 
using lymphocyte separation medium.  Cells are characterized using the flow 
cytometer forward and side scatter measures.  B. A transwell assay is used to 

















Real Time Reverse Transcription-PCR  (RT2PCR) 
 
To detect changes in mRNA levels,  HUVECs were treated for 0,1,6,12, and 24hr with 
various concentrations of IFN-α 2a  (PBL Interferon Source, Piscataway, NJ) or 20% 
SLE or control sera.   Cells were harvested following treatment and total RNA was 
extracted using a Trizol  (Life Technologies)-RNeasy® kit  (Qiagen, Frederick, MD, 
USA) hybrid protocol as previously described277. RNA integrity was assessed using a 
NanoDrop 2000c UV-Vis spectrophotometer  (ThermoScientific, Wilmington, DE, USA) 
and samples with A260/280 ratios of 1.8-2.1 were used.    Single strand cDNA was 
synthesized from 1ug of RNA using an iScript™ cDNA synthesis kit  (BioRad, Hercules, 
CA, USA ).  For each reaction, 1uL of cDNA product was used for signal amplification 
with SsoAdvanced™ universal SYBR®  (BioRad) in  a CFX96 Real Time PCR Detection 
System  (Bio-Rad Hercules, CA), was used to assess changes in NOS2, NOS3, CCL2, 
VCAM-1, ICAM-1, NOX2, NOX4, GAPDH, and RPL13A  using commercially available 
primers  (SABiosciences, Frederick, MD, USA).  The following additional 
oligonucleotide primers were used: PKR: Forward 5’CTT CCA TCT GAC TCA GGT 
TT—3’ and Reverse 5’ TGC TTC TGA CGG TAT GTA TTA—3’, IFIT1: Forward 5’ 
CTC CTT GGG TTC GTC TAT AAA TTG 3’and Reverse 5’- AGT CAG CAG CCA 
GTC TCA G -3’ , MX1: Forward 5’- TAC CAG GAC TAC GAG ATT G3’ and Reverse 
5’-TGC CAG GAA GGT CTA TTA G-3’. Each cycle was initiated for 3 minutes at 95ᵒC 





and annealing 55-60ᵒC  for 30s  depending on the primer sequence. Melt-curve analysis 
was set for 80 cycles with stepwise increments of 0.5ᵒC for 5s/step starting at 65°C. The 
relative expression was calculated using the equation 2-ΔΔCt.  The fold change gene 
expression of interest was calculated based on normalization to GAPDH or RPL13A 
housekeeping genes.  PCR was performed ≥ 3 independent experiments with at least 
three replicates.  
Measurement of Nitric Oxide Production 
 
For real time detection of NO production in HUVECs, 1.2x105 cells were seeded in a 12 
well tissue culture plate.  Following adherence, cells were serum starved for 6h in 
endothelial basal media  (EBM) containing 0.2% FBS.  Cells were stimulated with either 
50% healthy or SLE sera ± L-sepiapterin  (5uM; 6h), 1000IU IFN-α 2a  (30 min, 6h, or 
24h pre-incubation), the eNOS specific inhibitor L-NNA  (10uM; 30 min pre-incubate), 
or the NO donor DD1.  Following stimulation, cells were washed twice with PBS and 
loaded with 1uM DAF-FM diacetate  (4-Amino-5-Methylamino-2’,7’-
Difluorofluorescein Diacetate  (Invitrogen, OR, USA)  in phenol red free Endothelial 
basal media  (EBM) for 30-45 minutes. Cells were washed twice with PBS and 
stimulated with Insulin  (100nM, Sigma Aldrich) for an additional 20 minutes.  The 
stimulated cells were dissociated from  plates using phenol-red free TryPLE™ Express  
(Invitrogen) and fixed with 2% paraformaldehyde  (PFA) for 3 minutes.  A population of 
7,000-10,000 cells were gated and analyzed based on their fluorescence intensities using 
FACS Calibur  (Becton Dickenson; San Diego, USA).  The median fluorescence intensity 





discriminate between NO other gaseous molecules previously shown to augment DAF-
FM fluorescence, we performed an urate assay to optimize our assay.  
 
Neutrophil Adhesion Assay 
 
HUVECs were plated at 5.0x 104 cells/ml in a 24 well plate  (Costar) and allowed to 
adhere overnight. HUVECs were serum starved for 3h in phenol-red free 0.2% FBS EBM 
media  (Lonza) prior to activation with 10% sera or IFNα for 4 hours. TNFα  (100ng/ml) 
was used as the positive control. Neutrophils isolated from healthy human blood as 
outlined previously were labeled with Calcein AM  (Life Technologies) at 5x105 cells/ml. 
Neutrophils were washed gently four times in warm serum free EBM culture media prior 
to co-culturing with HUVECs for 60 minutes after which, non-adherent cells were 
removed by repeated gentle washing  (four times) with EBM culture media. Fluorescence 
intensity was measured at 520nM with a FLUOStar Omega microplate reader  (Cary, 
NC), and images were captured using confocal microscopy. See Figure 3-2 for a visual 





























Figure 3-2. A. Nitric oxide prevents neutrophil adhesion to the endothelial cell 
surface.  B. Neutrophil adhesion assay requires four different steps.  These include 
stimulation of endothelial cells with serum or interferon alpha, the cells are then 
washed and calcein AM stained neutrophils are added to the well.  The neutrophils 
are co-cultured with endothelial cells for one hour and all non-adherent cells are 
removed using gentle washing. Cells are then analyzed using a fluorescent 












Western Blot  
HUVECs in culture were serum starved overnight in EBM phenol red free media 
containing 0.1% FBS. Cells were treated with IFN-α  (1000IU/ml) at various time points 
and/or insulin 100nM for 15 minutes following IFN-α pretreatment. Cells were washed 
once with cold PBS and lysed using a 1X RIPA lysis buffer  (50mM Tris-HCl, ph 7.5, 
150mM NaCL, 1% Triton X-100, 0.5% deoxycholate, 0.1 mM EGTA, and 1mM EDTA, 
0.1% SDS, 100nM okadaic acid, 1:100 protease/phosphatase inhibitor cocktail  (Cell 
Signaling, Danver MA, USA). Protein concentrations were determined using the Bio-Rad 
Protein Assay  (Hercules, CA). Protein lysates  (30ug) were separated on precast 4-12% 
Tris-HCL Invitrogen gels and transferred for 12-18 hours at 40mAmps in transfer buffer  
(192mM glycine, 25mM Tris-HCl, and 20%  (v/v)methanol) onto a PVDF membrane. 
Following transfer, blots were rinsed for 10 minutes in 1X PBS and then blocked for 1h 
in Odyssey® Blocking Buffer, TBS  (Li-CR Biosciences, Lincoln/Nebraska, USA) at 
room temperature. Membranes were incubated overnight with mouse monoclonal 
antibody specific for eNOS, eNOS Ser1177, eNOS Thr495  (BD Biosciences) and β-actin  
(Cell Signaling, Danver, MA) were detected using their respective antibodies. Infrared 
dye goat anti-mouse secondary antibodies  (Li-COR Biosciences, Lincoln/Nebraska, 
USA) were used for signal enhancement, and all blots were visualized with the Odyssey 
scanner  (Li-COR Biosciences). Quantitative analyses of band intensity was performed 





Measurement of MCP-1 
 
MCP-1 concentrations in HUVEC supernatants were determined by enzyme-linked 
immunosorbent assay  (ELISA, eBioscience) according to the manufacturer’s instructions. 
 
Statistical Analysis and Data Handling 
 
Statistical analysis was conducted using IBM SPSS Software  (Armonk, NY) or 
GraphPad Prism Version 6.0f  (San Diego, CA). Gaussian distribution was determined 
using the D’Agostino-Pearson omnibus normality test and the Shapiro-Wilk normality 
test. Paired and unpaired  (where appropriate) Student’s t and nonparametric Mann-
Whitney test were used depending on the distribution of the data when data were 
normalized to control.   Analysis of variance  (ANOVA) and Tukey’s post-tests where 
data were normally distributed and Wilcoxin Rank’s Sum with Dunn’s post test was used 
to analyze neutrophil adhesion data.  Data are presented as mean ± standard deviation. 






Chapter IV Specific Methods 
 
Neutrophil Migration Assay 
 
Transwell migration assays were performed as described elsewhere.  Briefly, transwell 
inserts  (3um pore) were pre-coated with fibrinogen and allowed to incubate overnight for 
24 hours.  HUVECs were seeded in 24 well plates at 1.0 x 104 cells per well and allowed 
to adhere overnight. Cells were activated with 50% sera from healthy and SLE controls 
for 6hrs and washed once in PBS.  Neutrophils were added to chambers and inserted into 
media ± IL-8.  After 60 minutes, the number of neutrophils in the lower chambers using 
confocal microscopy. See figure 3-1 for a visual depiction of the assay.  
 
Low Temperature Electrophoresis  (Uncoupling Assay) 
 
To determine the impact of sera on changes in eNOS dimer/monomer ratios, low 
temperature electrophoresis was conducted.  Growth arrested HUVECs were treated with 
50% healthy or control sera in the presence or absence of L-sepiapterin  (5uM) for 6h. 
Cells were washed in ice-cold PBS and lysed in Tritox-X 100 buffer supplemented with 
protease/phosphatase inhibitors  (1:100) and okadaic acid  (1000nM).  Nupage sample 
buffer  (4x) was added to samples and lysates were incubated for 5 minutes in a 37C 
water bath prior to electrophoresis.  NuPAGE Novex 3-8% Tris-Acetate gels  




gel.  Electrophoresis and transfer were performed on ice at 4C and membranes were 
subsequently probed for eNOS and β-actin. 




HUVECs were cultured at 5x105 cells per ml and allowed to adhere overnight.  Cells 
were treated with various compounds and assayed following the protocol provided with 
the cGMP commercially available assay kit  (cGMP EIA Biotrak,GE Healthcare, HK 
Limited, Buckinghamshire, UK). 
 
Heteronuclear RNA Assay    
 
cDNA was synthesized as outlined above.  The following primer sequence for 
heteronuclear eNOS RNA was used: Forward-5’-ACC CTC ACC GCT ACA TC-3’ and 
Reverse 5’-C GGG GAC AGG AAA TAG TTG A-3’. PCR Master Mix  (Promega, 
Fitchburg, WI, USA) was used for PCR.  Each cycle was initiated for 3 minutes at 95°C 
followed by 40 cycles of 45s at 95°C, 45s at 49°C, and 45s at 72°C.  The final cycle was 
ran at 72°C for 7 minutes.  Samples were separated on a 1.5% agarose gel, and bands 
were quantified using Image J Software  (NIH, Bethesda Maryland). Commercially 
available S26 was used as the internal control, and values are reported as the mean and 





Actinomycin D Stability Assay 
 To determine changes in NOS3  (eNOS) mRNA stability, cultured HUVECs were 
pretreated with Actinomycin D  (5ug/ml, Sigma Aldrich) for 2hrs followed by treatment 
with IFNα  (1000IU/ml) and TNFα  (100ng/ml, control)  for 6 and 24hrs. Samples were 
processed for RNA extraction as described above and assayed accordingly using RT2PCR.  
β-actin was used as the internal housekeeping control.  
Transfection of PKR and NF-kB-specific siRNA into endothelial cells 
 
PKR, NF-κB, and negative control siRNA were purchased from Invitrogen  (Grand 
Island, NY, USA).  HUVECs were plated at 1.0*10^5 cells per well in a six well plate 
and allowed to adhere overnight.  Cells were then transfected using Lipofectamine® 
RNAiMAX reagent according to the manufacturer’s instructions. After 24-36h, cells 
were stimulated with IFN-α  (1000IU/ml) for 6h and RNA was isolated to examine 
changes in eNOS gene expression using RT2PCR. 
 
Analysis of microRNA 155 Expression 
 
Real Time RT-PCR analysis was conducted using a relative quantification  (ΔΔCT) 
method to calculate changes, and all values were normalized to untreated samples. 
Analysis was performed using a TaqMan MicroRNA Reverse Transcriptase Kit and the 
individual TaqMan MicroRNA 155 assays  (Applied Biosystems, Grand Island, NY, 




and expression of mature hsa-miR-155  (assay ID: TM 002623) was determined using 
CFX96 Real Time Detection System as outlined previously. RNU6B  (assay ID:001093) 





























SLE Serum Induces eNOS 
Uncoupling in Human Umbilical 







Myocardial infarction, preceded by accelerated atherosclerosis, constitutes a 
major cause of morbidity and mortality in patients with SLE. Immune dysregulation 
contributes to poorer prognosis in cardiovascular disease outcomes in SLE; however, the 
exact mechanisms are unknown. SLE serves as an independent risk factor for endothelial 
dysfunction, which precedes atherosclerotic plaque development.  Endothelial integrity 
preservation occurs when endothelial nitric oxide synthase  (eNOS) activity and nitric 
oxide  (NO) bioavailability are intact.  
Biopsies isolated from patients with severe lupus nephritis show diminished 
eNOS expression; while we previously reported that MRL/Faslpr/J mice deficient in 
eNOS developed increases in proteinuria had lower rates of survival. These findings 
indicate that advanced vascular disease occurs in a lupus-like microenvironment in the 
absence of eNOS. Patients with CV risk factors  (i.e. diabetes, hypertension, and 
smoking) have diminished flow mediated brachial artery dilation, a surrogate marker of 
endothelial dysfunction. Further, in vitro studies using serum from these patient 
populations confirmed alterations in eNOS  (NOS3) mRNA levels and diminished NO 
bioavailability from endothelial cells; a phenomenon mainly due oxidative stress-induced 
eNOS uncoupling.  
   Oxidative stress is an imbalance in the production and neutralization of reactive 
intermediates  (i.e. reactive oxygen species, reactive nitrogen species).  Sources of 
superoxide in the endothelium include gp91 phox  (Nox2), Nox4, and mitochondrial 




mellitus, and hypercholesterolemia) promote generation of reactive oxygen species  
(ROS) including hydrogen peroxide  (H2O2) and superoxide  (O2.-) leading to endothelial 
dysfunction.   
Controversy regarding the role of eNOS gene expression in NO bioavailability 
persists.   Several studies have implicated an increase rather than a decrease in eNOS 
expression in response to cardiovascular risk factors including hypertension278, 
diabetes279, 280, and smoking.  Accordingly, a positive correlation between H2O2 and 
eNOS levels in vitro 180. Paradoxically, NO produced in the presence of O2.- yields 
peroxynitrite  (ONOO-).   Peroxynitrite oxidizes the essential eNOS co-factor BH4 to 
dihydrobiopterin  (BH2) and biopterin which results in ROS rather than NO production 
281, 282.   
In the present study, we used human umbilical vein endothelial cells to study the 
impact of SLE serum on eNOS expression and NO production in vitro.  We report for the 
first time that SLE serum induces NOS3 expression and suppresses NO production in 
HUVECs.  Importantly, we show that L-sepiapterin, a precursor of BH4 synthesis, 
restores abnormal NO production in lupus sera cultured endothelial cells leading to 
restoration of eNOS dimer/monomer ratios.  Further, we report that SLE serum induces 
neutrophil chemotaxis and adhesion to the endothelial cell surface; but, L-sepiapterin 
fails to impair SLE-serum mediation neutrophil adherence.  These results point to a role 







SLE sera enhances NOS3 mRNA Abundance 
 
Compared with healthy controls, SLE serum induced NOS3 mRNA < 2-fold  
(Figure 4-1A), which may suggests that mediators present in SLE serum are inducing 
oxidative stress.  
 It is well established that aging is a risk factor for endothelial dysfunction and 
cardiovascular disease; thus, we examined correlations between NOS3 mRNA and age in 
controls versus SLE patients  (Figure 4-1B) and observed a significant negative 
correlation with age in the SLE group  (rho= -0.5884, p=.0025) but, not in controls. 
Similar significant correlations were found   NOS3 mRNA levels did not correlate with 
SLE disease activity index  (SLEDAI) scores  (r=0.2482 and p=0.2419; Figure 4-2A, B), 
however; a positive correlation was identified with SLICC scores  (r=0.3550 and 
p=0.0887).  Similarly, no correlation was found between NOS3 mRNA levels and 
prednisone use status  (Figure 4-2C).  
 Due to NOS3/eNOS modulation of blood pressure regulation 283, 284, we examined 
associations between systolic and diastolic blood pressure with NOS3 mRNA  (Figure 4-
2D, E).  We observed an association between NOS3 mRNA induction and systolic but not 
diastolic BP  (r=-0.5176 and p=0.0590 and r=0.2399 and p=0.3709, respectively). 
Studies supporting a role for type I interferons in the pathogenesis of endothelial 




NOS3 mRNA levels.  Type I interferon signature gene analysis indicated that protein 
kinase R gene induction negatively correlated with NOS3 mRNA levels  (r=-0.442, 
p=0.031; Figure 4-3A).  While MX1 and IFIT1 did not  (Figure 4-3B, C). 
 Given that our cohort had relatively low Framingham risk factors  (4% smokers 
and 4% diabetic), and  the fact that age, PKR, SLICC scores and blood pressure all 
modulate the inflammatory response in vivo and in vitro, lupus specific-inflammatory 



















Figure 4-1. SLE Sera induces NOS3 mRNA expression in human 
umbilical vein endothelial cells.   A. Induction of NOS3 mRNA is 
significantly increased by 20% SLE serum versus healthy serum. The 
scatter plot represents the mean fold change and error bars are the 95% 
confidence intervals whiskers of 14 healthy and 25 SLE patient samples. 
Analyses were performed using a student’s T-test  (**p<0.01).  B. Lupus 
induced NOS3 mRNA levels correlate with patient age but, not in 
healthy serum samples.  NOS3 is plotted as a function of individual 
patient age. Lines are drawn based on linear regression and 




























Figure 4--‐2.  Correlative associations between SLE sera mediated NOS3 
mRNA induction and clinical parameters.  A. Changes in NOS3 mRNA 
levels do not correlate with disease activity. NOS3 mRNA levels are 
plotted as a function of SLEDAI scores in individual patients. B. 
Altered NOS3 mRNA levels associate but do not significantly correlate with SLE 
damage index  (SLICC) scores. NOS3 mRNA levels are plotted as a function of 
SLICC scores for individual patients. C. Lack of association between NOS3 
mRNA and prednisone use status. The graph represents the average fold change 
in NOS3 mRNA levels in patients with or without prednisone in their daily 
therapeutic cocktail.  Error bars are 95% confidence intervals. D. Changes in 
NOS3 mRNA levels correlate with systolic blood pressure in 
individual patients. NOS3 mRNA levels are plotted as a function of 
systolic blood pressure.  (E) NOS3 mRNA does not associate with diastolic 
BP. Analysis were performed using a Spearman’s rho test and values were 































































Figure 4-3. NOS3 mRNA correlates with PKR induction by SLE serum. A-C. 
Correlation between NOS3 mRNA and PKR, MX1, and IFIT1 induction by SLE 
serum.  Statistical analysis was performed using the Spearman’s rho  (r) 
























HUVECs stimulated with SLE Serum Display Abnormal NO production 
 
To determine the impact of serum on NO production using protocols outlined in 
the materials and methods section, we stimulated HUVECs with 50% healthy or SLE sera.   
Control serum clearly suppressed NO production but these changes were not significant  
(Figure 4-4A), indicating that factors present in serum in vitro  (absent of shear stress) 
may alter basal NO levels, as measured by DAF-FM intensity. Strikingly, SLE serum 
stimulation lead to an 80% decrease in NO production compared to EGM-2 medium 
cultured cells  (Figure 4-4B).  The paradox of increases in NOS3 mRNA and diminished 
NO is a hallmark of eNOS uncoupling.  
L-sepiapterin is a precursor for tetrahydrobiopterin  (BH4) synthesis and previous 
studies have shown its efficacy in restoring eNOS function, possibly through a re-
coupling mechanism.  To test the hypothesis that L-sepiapterin could restore eNOS 
dimerization, we conducted a proof of principle experiment examining differences 
between eNOS monomer/dimer levels in response to L-sepiapterin. Indeed, increases in 
dimer levels, as measured by western blot, were observed in all treatment groups  (i.e. 
EGM-2 buffer, controls, and SLE) with L-sepiapterin  (Figure 4-5A).  
Next, to further understand the therapeutic efficacy of L-sepiapterin in reversing 
NO loss, we co-cultured cells with serum and L-sepiapterin and observed significant 
restoration of NO production in healthy and SLE serum induced cells  (SLE: 
0.6604±0.6812 vs L-sepiapterin buffer control: .0.7603±0.7793)  (Figure 4-6A-C). 
Collectively, this body of data suggests that factors present in lupus serum may augment 


















Figure 4-4. SLE serum impairs NO production in HUVECs.  A. A histogram 
of one representative control and one representative SLE sera treated HUVEC 
culture sample displaying changes in DAF-FM fluorescence intensity. The gray 
represents the buffer control, the green line represents control serum, and the red 
line represents SLE serum.  Total events for acquisition were 7,000.   B. Results 
represent the fold change median fluorescence intensity normalized to buffer 
controls ± SD.  Analyses were conducted using a 2-Way Anova and Bonferonni’s 







































Figure 4-5. L-sepiapterin promotes eNOS dimerization. A. A western blot 
of eNOS monomers  (140kDa) and dimers  (200kDa) from one representative 
control, healthy sera, and SLE sera treated HUVECs with and without L-
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Figure 4-6. L-sepiapterin restores NO production in SLE sera treated 
HUVECs. A - B .  One representative sample of DAF-FM intensity in 
HUVECs stimulated with healthy serum with and without L-sepiapterin. Buffer control  
(gray), L-sepiapterin  (blue), healthy serum  (light green), and healthy + L-
sepiapterin  (dark green) samples are represented in panel A while SLE serum  
(red) and SLE serum + L-sepiapterin  (orange) are represented in the panel B. 
Total events for acquisition were 7,000.   C. Results represent the fold change 
median fluorescence intensity normalized to buffer controls ± SD. Analysis was 
conducted using a 2-Way Anova and Bonferonni’s post test of 12 buffer, 5 













SLE Serum Induces Neutrophil Chemotaxis and Neutrophil Adhesion  
 
Neutrophil extracellular traps play a prominent role in the development of 
endothelial dysfunction leading to atherosclerosis.  Neutrophil chemotaxis in the context 
of IL-8 production yields neutrophil netosis, a phenomenon recently associated with 
activation of matrix metalloproteinaise-2  (MMP-2), a known modulator of endothelial 
function, by MMP-9 within neutrophils.  Thus, the ability of SLE serum to induce 
neutrophil chemotaxis may serve as a functional consequence of eNOS impairment, as 
correlations between MMP-2/MMP-9 and NO bioavailability have previously been 
observed.  
As with earlier studies, we treated endothelial cells with 50% SLE serum for 6hrs 
prior to addition of neutrophils to transwell chamber and changes in migration were 
assessed.  Contrary to our initial hypothesis, our studies suggest that SLE patients have 
higher neutrophil/endothelial cell ratios compared to healthy controls  (SLE: 0.99±0.54 
vs healthy: 0.50±0.15; Figure 4-7A,B).  
To further assess SLE mediated functional consequences of changes in NO, we measured 
changes in neutrophil adhesion to the endothelial cell surface in response to SLE sera.  
Unlike control sera, SLE sera treated cells had significantly higher levels of neutrophil 
adhesion to the endothelial cell surface compared to buffer control  (SLE: 0.1808±0.0709 
vs control: 0.1202±0.0841, p<0.001).  Surprisingly, the addition of L-sepiapterin did not 
reverse the proatherogenic phenotype induced by SLE sera as there were significant 
differences detected between lupus cultures supplemented with L-sepiapterin and L-




be partially responsible for deficient NO levels in response to SLE serum but does not 


























































Figure 4-7.   Lupus serum induces neutrophil chemotaxis 
A. HUVECs were stimulated for 6h with 50% control or lupus serum and 
transwell inserts containing 50,000 neutrophils /well were placed as outlined in the 
materials and methods section. Images are representative of 2 of 2 buffer controls, 
1 of 1 IL-8 controls, 4 of 5 healthy serum, and 4 of 5 SLE serum samples.  Images 
represent calcein AM  (top) and bright field + calcein AM  (bottom) of neutrophils 
that migrated to endothelial cell layers stimulated with serum  (10X objective 
magnification). B. The graph represents the ratio of neutrophils/endothelial cells 
±SD of 2 buffer controls, 1 IL-8 control, 5 healthy controls and 5 SLE serum 
samples. All data were analyzed using Kruskal-Wallis Anova and Dunn’s post-test.  





























Figure 4-8. Lupus serum induces neutrophil adhesion to the endothelial cell 
surface.  A. HUVECs were stimulated for 6h with 10% serum and exposed to 
neutrophils isolated from fresh human blood as outlined in materials and methods.   
Images are representative of 5/5 buffer control, 6/8 SLE serum, and 3/3 healthy 
serum samples.  Images represent calcein AM  (left), and bright field merged with 
calcein AM  (2nd column), calcein AM + L-sepiapterin  (3rd column), and merged 
+ L-sepiapterin  (right) of HUVEC cells exposed to buffer  (top), control serum  
(middle), or SLE serum  (bottom; all images were taken at 10X magnification).  
The green represents neutrophils adhered to the endothelial cell surface. B. Graphs 
represent the mean ratio of adhered neutrophils/endothelial cells ±SD.  
Quantification of neutrophils is reported as means ±SD of 5 buffer controls, 9 SLE, 
and 3 controls.  **p<0.01 as compared to buffer control.  All data were analyzed 































We’ve shown that SLE serum induces endothelial dysfunction by augmenting 
eNOS mRNA levels, reducing NO production, and enhancing neutrophil adhesion to the 
endothelial cell surface.  Our results also show a role for eNOS uncoupling in response to 
SLE serum which is reversed with L-sepiapterin supplementation.  
Endothelial dysfunction is the initial step in the development of premature 
cardiovascular disease complications identified in SLE patients yet, the mechanisms 
leading to accelerated CVD risk are missing.  Our group has proposed a prominent role 
for eNOS deficiency leading to more pronounced vascular diseases in SLE.  Indeed, 
abnormalities in endothelial dysfunction have been attributed to eNOS uncoupling in 
multiple vasculopathies.    
Controversy persists as to whether or not eNOS mRNA abundance is a crucial 
parameter for predicting endothelial derived NO production as a number of studies in 
vascular disease models including smoking, ageing, and diabetes have not provided 
definitive results.  Interestingly, in our SLE serum induced HUVECs, we observed an 
increase in eNOS mRNA levels that negatively correlated with patient age and protein 
kinase mRNA induction. Ageing is known to greatly impact endothelial dysfunction as 
multiple studies have reported a direct correlation between patient age and FMD.  Still, 
specific-SLE serum factors associated with ageing in SLE have yet to be revealed. 
Importantly, these associations were not observed in control sera treated cells.  Protein 
kinase R is an interferon inducible gene previously shown to associate with declines in 




While the exact role of PKR in endothelial cell regulation is obscure, potential 
mechanisms include impairment of genes that support eNOS regulation and 
phosphorylation of the p65-NF-kB subunit which may indirectly impact eNOS 
transcription.  Further, studies show that PKR impairs insulin growth factor mediated 
signaling where one of its most well studied targets is eNOS.  
Our study reports the following findings:  (1) NO production in SLE induced 
endothelial cells is diminished compared to buffer controls and healthy sera cultures 
which coincide with previous findings that sera from populations at risk for endothelial 
dysfunction deplete  basal eNOS derived NO levels in vitro285.  Since NO production is 
important for anti-atherogenic pathways and protection of the endothelium, loss of NO 
may accelerate the development of endothelial dysfunction observed in SLE patients.  
Further, changes in NO production coincided with MX1 and IFIT1 interferon signature 
gene expression.  Nonetheless, our studies were not powered to truly assess the 
association between NO production and IFN signature genes which may implicate a role 
for IFNα in the deregulation of eNOS in vitro.  Thus, future studies are needed that may 
explain the effects of Type I interferons on these pathways.   (2) Lupus sera induced 
changes in NO production are reversed with addition of L-sepiapterin.  Since L-
sepiapterin serves as a precursor for BH4 synthesis by GTP cyclohydrolase I and BH4 is 
an essential co-factor for NO generation by NOS enzymes, it’s possible that SLE sera 
may induce pathways that promote BH4 oxidation and depletion in vitro.   (3) SLE 
cultured endothelial cells have an increased capacity to bind neutrophils compared to 
buffer treated cells.  These findings suggest that factors present in serum may induce 




consequences due to diminished NO.   (5)  Surprisingly, we did not observe diminished 
neutrophil adhesion with the addition of L-sepiapterin.  Additional studies examining 
optimal concentrations for therapeutic efficacy are needed.  Supporting this claim, others 
have shown that sepiapterin supplementation reduced post-ischemic myocardial 
infarction injury by ameliorating NO-mediated cGMP levels and reducing 
myeloperoxidase activity associated with neutrophil activation 286. Impaired eNOS 
function along with additional mechanisms may contribute to diminish NO 
bioavailability as well.  
 Our results implicate a role for factors in SLE sera that may contribute to 
endothelial dysfunction via eNOS uncoupling.  We have previously reported that eNOS 
is protective against vascular disease manifestations in SLE287 .  Since NO production is 
crucial for adequate vessel relaxation and atherosclerotic plaque prevention, we 
hypothesize that therapeutic interventions restoring eNOS coupling may strongly 
promote vascular endothelial function and subsequent prevention of premature 
atherosclerosis observed in SLE.  This proposal is supported by multiple observations.  
Prospective studies provide evidence that BH4 supplementation restores endothelial 
function in high risk cardiovascular disease patient populations including coronary artery 
disease, hypercholesterolemia, hypertension, and diabetic vasculopathy 288, 289, 290.  
Further, BH4 supplementation was shown to prevent neutrophil adhesion and 
transmigration in a myocardial ischemia/reperfusion injury rat model which suggest that 
BH4 overcomes inflammatory signaling mechanisms associated with tissue injury. 
 Overall, our results strongly support a role for SLE serum mediated changes in 




Although mechanisms leading to these changes are unclear, we show strong correlations 
between interferon inducible gene expression and alterations in eNOS and NO mediated 
by SLE sera.  Future studies will need to assess changes in eNOS and NO production in 
vitro following Type I interferon neutralization. Nevertheless, our results extend the 
clinical understanding of SLE in attenuating endothelial function.  Future interventions 
targeted at eNOS preservation may reverse premature atherosclerosis observed in SLE.  
The relevance of our findings may be applied to other populations developing endothelial 














Interferon alpha contributes to 
endothelial dysfunction possibly by 
upregulating miR155 and impairing 








Unexplained by conventional risk factors  (i.e. smoking, diabetes), systemic lupus 
erythematosus  (SLE) patients have as much as a 50-fold increase in cardiovascular 
disease 38, 291, 292.  Inflammatory mediators are associated with accelerated atherosclerotic 
plaque development in SLE 293; still, mechanisms explaining these complications are not 
well characterized.   
SLE patients display lower levels of circulating endothelial progenitor cells  
(EPC), a hallmark sign of endothelial dysfunction, 294, which strongly associates with 
type I interferon  (IFN) signature induction 295.  In fact, approximately 50% of SLE 
patients have an interferon signature gene expression in their PBMCs 296. The type I 
interferon signature is associated with SLEDAI Score, impaired vascular repair, and 
increased vascular inflammation 297, 298.  Depletion of IFNα in SLE sera lead to improved 
EPC monolayer formation in vitro 237.  Further, genetic ablation of the IFNAR in NZB/W 
lupus prone animals improved acetylcholine-mediated aortic constriction and EPC 
circulation 230. These studies indicate that type I interferons are important in promotion of 
premature endothelial dysfunction and may promote atherosclerosis in SLE. 
The pathogenesis of endothelial dysfunction is multifactorial; however, many 
signaling pathways converge on the diminished activity of endothelial nitric oxide 
synthase  (eNOS) and loss of nitric oxide  (NO) bioavailability.  NO is an anti-
atherogenic gaseous molecule that regulates blood vessel relaxation, platelet aggregation 
299, 300, 301, 302, leukocyte chemotaxis and, leukocyte adhesion.    
Hypercholesterolemia 302, 303, smoking 304, and elevated CRP levels 305, 306 are 




In hypercholesterolemia, oxidative stress induced by elevated LDL levels is thought to 
induce eNOS uncoupling307.  Moreover, cigarette smoke causes eNOS uncoupling and 
shifts the eNOS phosphorylation pattern to an inhibitory state in vitro 308.  Nevertheless, 
loss of NO-dependent flow mediated dilation  (FMD) has been reported in numerous 
diseases, including coronary artery disease 309 and type I diabetes 310.  
Given the high levels of type I IFN signatures observed in SLE patients and 
previously identified correlations between type I IFNs and impaired vascular function, we 
hypothesized that one way that IFN-α may contribute to endothelial dysfunction is by 
impairing eNOS activation and NO production in human endothelial cells. This study 








HUVEC myxovirus resistance protein 1  (MX1) and protein kinase r  (PKR) 
are induced by SLE Serum  
 
Prior to the investigation of IFN-α mediated endothelial dysfunction in HUVECs, IFN 
signature gene induction by SLE sera was investigated to determine physiologically 
relevant levels of type I IFN for future experiments. We selected PKR and MX1 due to 
their previously identified strong association with IFNα and disease activity in lupus 
patients 296, 311. Moreover, IFNα neutralizing antibodies can inhibit IFIG expression in 
healthy donor PBMCs cultured in SLE serum, strongly supporting a dominant role for 
IFNα in IFIG expression.  Treatment of HUVECs with 20% SLE serum for 24 hr. 
induced a 4.9 fold increase in PKR mRNA  (Figure 5-1A) and a 493.2 fold increase in 
MX1 mRNA  (Figure 5-1B) over buffer treated HUVECs. Following recombinant IFN-α 
a concentration curve experiments, we observed that treatment of cells at a 1000IU 
concentration induced PKR  (Figure 5-1C) and MX1  (Figure 5-1D) to levels 
commensurate with SLE serum at 20%. Therefore, this concentration of IFN- α was used 





















Figure 5-1. SLE Serum induces type I interferon signature gene expression in 
HUVECs.  A-B. HUVECs were incubated with 20% SLE serum or IFN-α for 24 
hours and cellular RNA was subjected to cDNA synthesis. RT2PCR was used to 
assess changes in gene expression. PKR and MX1 were induced by 24 SLE serum 
samples in HUVECs. Graphs display dot plots of the fold change induction 
normalized to GAPDH and error bars are 95% CI whiskers. C-D. PKR and MX1 
induction by IFN-α at various concentrations. Each bar graph represents the mean 
± SD for 3-6 IFNα treatment groups; *p<0.05, **p<0.01, ***p<0.001.  Statistical 
analysis for patient samples was performed using a Student’s T-test.  A One-Way 
















IFN-α impairs eNOS expression in HUVECs 
 
Type I interferon signature gene induction correlates with decreases in endothelial 
function in SLE patients thus, we hypothesized that type I interferons may negatively 
impact NOS3 mRNA levels.  Supplementation of culture media with IFNα suppressed 
eNOS gene expression in a dose and time dependent manner after 6 and 24 hours  (50% 
and 77%, respectively; Figure 5-2A,B). In titration experiments, declines in eNOS gene 
expression negatively correlated with PKR  (R2 =0.9855) and MX1  (R2 =0.8555)  (Figure 
5-2C-D). Supporting the functional significance of reduced gene expression, HUVECs 
treated with recombinant IFNα for 6 and 24 hours  (Figure 5-3A-B) had lower levels of 
total eNOS protein when compared to buffer treated controls  (6 hours:1.00 vs. 0.41, 




































Figure 5-2. IFN-α impairs eNOS gene expression. A. HUVECs were incubated 
with IFN-α and cellular RNA was subjected to cDNA synthesis and qRTPCR as 
implicated in the materials and methods section.  NOS3 mRNA expression in 
HUVECs treated at various IFN-α concentrations B. or time points C. MX1 D. 
PKR correlative expression with NOS3 mRNA. Each bar graph represents the 
mean ± SD.  **p<0.01, ***p<0.001, n=3-6. Statistical analysis were performed 





































Figure 5-3. IFN-alpha reduces eNOS protein abundance. A. Cell lysates from 
HUVECs stimulated with IFN-α  (1000IU/ml) for 6h and 24h were immunoblotted 
for eNOS and b-actin., B. The graph represent the mean of the fold change 
normalized values ± SD, n=3.  *p<0.05, **p<0.01.  Western blot data was 































IFN-α reduces NO Production In Vitro 
 
Due to the observed changes in eNOS gene and protein expression, we hypothesized that 
NO levels would also reduce with IFN-α treatment. HUVECs exposed to IFN-α for 6h 
displayed lower levels of DAF-FM fluorescence as a surrogate for NO production versus 
media alone  (1±0.08 vs 0.4696±0.1192, p=0.001, Figure 5-4A,B). There were no 
differences after 24h of treatment.  
Next, we assessed the impacts of IFN-α on insulin-mediated activation and found 
that insulin-stimulated NO production in vitro at both 6 and 24 h was significantly 
impaired  (1.047 vs 0.667, p=0.0148 and 1.047 vs 0.6847, p=0.0022, respectively; Figure 
5-4A, B). These data suggest that reduced protein levels may contribute to IFN-α-
mediated NO loss and may potentiate IFN-α mediated “insulin resistance.” Further 
assessment of functional consequences of reduced NO production revealed a 37% 
reduction in cGMP bioavailability after culture of HUVEC with IFN-α in vitro  (p<.01, 

































Figure 5-4. IFN-alpha reduces nitric oxide production in HUVECs.  
 A. Histograms representing changes in DAF-FM intensity following stimulation 
with buffer  (gray), insulin 100nM  (blue), IFNα  (red), or IFNα + insulin  (green) 
at various time points. Total events acquisition was 10,000.  B. MFI quantification 
of HUVECs loaded with 1uM DAF-FM diacetate.  Samples were analyzed using 
flow cytometry following IFNα treatment at the specified times. Means of the 
median fluorescence intensity are reported ± SD, n=3-9. *p<0.05, **p<0.01 as 
compared to buffer control and Φp<0.05 and ΦΦp<0.01 compared to insulin 
control.  Flow cytometry data was analyzed using a Two-way Anova and 



































































Figure 5-5. IFN-alpha reduces cGMP production in HUVECs.   
A. HUVECs were stimulated for 6h with IFN-α.  Cell lysates and supernatants 
were assayed using a cGMP EIA kit as outlined in materials and methods. 
Differences are reported as percentage of control±SD; n=3 **p<0.01.  cGMP data 























IFN-α enhances adhesion molecule expression and monocyte chemoattraant 1 






Nitric oxide prevents intracellular adhesion molecule 1  (ICAM-1) expression and 
monocyte chemoattractant protein 1  (MCP-1) production in endothelial cells. This leads 
to down regulation of neutrophil adhesion to the endothelial cell surface that is necessary 
for ultimate transmigration of inflammatory cells 312.  
Leukocyte adherence anchors expressed on the endothelial cell surface include, 
among others, intracellular adhesion molecule-1  (ICAM-1) and vascular adhesion 
molecule-1  (VCAM-1). Moreover, recent studies have proposed that MCP-1 is important 
for neutrophil recruitment to the endothelial cell surface 313. Hence, we examined changes 
in IFN-α mediated ICAM-1 and MCP-1 induction.  
HUVECs cultured in IFN-α displayed higher levels of ICAM1; although, 
differences were not significant  (p=0.068). MCP-1  (CCL2) as well as VCAM-1 
expression were significantly increased compared to buffer controls  (p<.0001 and 
p=0.0124, respectively). Moreover, we observed that supernatant MCP-1 protein levels 
also increased in response to IFN-α, which further confirms a functional role for IFN-α 
in immune cell chemotaxis and adhesion to the endothelial cell surface  (Figure 5-6A, C 
and Figure 5-7A,B).  When S-nitrosoglutathione  (GSNO) was added to cells in the 
presence of IFN-α, MCP-1 levels were significantly reduced, suggesting that IFNα 
mediated increases in MCP1 may be dependent upon loss of NO production  (Figure 5-
6B). 
As a functional assay, we wanted to assess the impact of IFN-α on this NO-modulated 
process in vitro. HUVECs treated with IFN-α for 6h did not display enhanced neutrophil 
adhesion to the endothelial cell surface.  (119300 ± 705.1 vs. 94908± 5869 relative 

















Figure 5-6. IFN-alpha induces monocyte chemoattractant-1 expression 
and production in HUVECs. HUVECs were stimulated for 6h with IFN-α 
and RNA isolates or cell supernatant was assayed using RT2PCR or an 
ELISA as outlined in the materials and methods section. A-B. CCL2 mRNA 
expression after a 6 hour stimulation with IFNα, normalized to GAPDH.  
CCL2 induction was enhanced with IFNα treatment as previously shown. 
GSNO was able to reverse IFNα induction of CCL2.  Results are mean 
fold change ± SD. C. Interferon alpha cultured cells assayed for MCP-1 
protein. Means are reported ±SD of 6 buffer controls and 6 IFNα treated 






























Figure 5-7. IFN-alpha induces adhesion molecule expression.  HUVECs were 
stimulated for 6h with IFN-alpha and RNA isolates were assayed using RT2PCR 
as outlined in the materials and methods chapter.  A. mRNA expression of 
VCAM-1 and B. ICAM-1, normalized to GAPDH.  VCAM-1, but not ICAM-1, 
was significantly induced by IFNα treatment.  Results represent the fold change of 
the mean expression ±SD of n=3 for each treatment group. *p<0.05 as determined 






































Figure 5-8. IFN-alpha does not enhance neutrophil adhesion to the 
endothelial cell surface.  A. HUVECs were stimulated for 6h with IFNα and 
calcein AM stained neutrophils were added to cultures for 1hr. Wells were gently 
washed and differences in fluorescence were assessed. Images are representative 
of 4 of 4 buffer controls and 3 of 4 IFNα treatment groups. Images represent 
calcein AM  (top) and bright field merged with calcein AM  (bottom);  (40X 
magnification). B. Graph represents the fold change of the mean of relative 





























Protein Kinase R induction associates with SLE serum mediated declines in 
eNOS gene expression 
 
To establish the potential in vivo relevance of these findings in SLE, we analyzed levels 
of PKR and MX1 induction by SLE serum in relationship to eNOS. The eNOS gene 
expression was down regulated in a PKR-dependent manner  (r=-0.63, p=0.0009), as 
shown in chapter IV.  However, eNOS did not associate with MX1 induction  (Figure 5-
9A, B). To determine if PKR directly regulated IFN-α-mediated changes in eNOS gene 
expression; we used siRNA to knockdown PKR expression in HUVECs and determined 
changes using RT2PCR. IFN-α treated HUVECs deficient in PKR had 30% lower levels 
of eNOS  (Figure 5-10A, B).  PKR is known to enhance NF-κB activity 314, while NO 
ameliorates it via S-nitrosylation of the p50 subunit 226, 315, 316. NF-κB is a pleiotropic 
mediator of immune responses and inflammatory gene control. Thus, we sought to 
determine if NF-kB activation was partially responsible for diminished eNOS expression 
in response to IFNα.  After a 6h IFNα treatment, eNOS increased 50% in NFκB deficient 
cells over cells transfected with negative siRNA oligonucleotides  (Figure 5-10 C,D). 
This suggests that the effect of IFNα on eNOS may be partially due to activation NFkB 




























Figure 5-9. NOS3 mRNA correlates with PKR induction by SLE serum. A. 
SLE serum induces expression of PKR in HUVECs and this induction negatively 
correlates with altered NOS3 gene expression.  The dot plot is representative of 24 
SLE patients and NOS3 is graphed as a function of PKR. B. SLE serum induces 
MX1 gene expression in HUVEC cells but this induction lack association with 
NOS3 gene expression. Statistical analysis was performed using the Spearman’s 
































































Figure 5-10. NF-kB silencing restores NOS3 expression.  A-D. mRNA 
expression of PKR, NOS3, and NF-kB genes following siRNA transfection for 
30h and IFN-α  (1000IU/ml) treatment for 6 hours. Samples are normalized to 
GAPDH. No differences were detected in NOS3 mRNA in HUVECs deficient in 
PKR although, there were declines in NOS3 mRNA levels. However, NOS3 
mRNA levels were restored with NF-kB silencing.  Results are fold change of the 




















Declines in eNOS gene expression are due to enhanced mRNA instability, 
possibly through miR155 induction 
 
Previous studies have demonstrated that declines in eNOS mRNA abundance may 
occur through changes in transcription and post-transcriptional modifications.  
Surprisingly, IFNα enhanced heteronuclear RNA levels, a surrogate measure of 
transcriptional rates  (Figure 5-11A).  However, IFN-α co-culture resulted in a significant 
9% decline in eNOS mRNA half-life at 22h compared to control  (Figure 5-10B).  
MicroRNA binding to the 3’ UTR region of human eNOS destabilizes the enzyme. We 
investigated whether IFNα induced miR155, which was previously shown to destabilize 
eNOS 317.  Treatment with IFN-α substantially increased miR155 expression compared to 
controls  (Control:1.000 ± 0.3381 vs IFN-α 1.5223± 0.2133, p<0.05; Figure 5-11C).  
However, our studies were not adequate to determine if IFN-α mediates decreases in 































Figure 5-11. IFNα promotes NOS3 mRNA instability. A. NOS3 heteronuclear 
RNA expression following treatment of HUVECs with IFN-α  (1000IU/ml). 
Values are normalized to S26.  B. Cells were incubated with 5ug/ml Actinomycin 
D for 2 hours to stop transcription.  IFNα  (1000IU/ml) or negative control  (TNFα 
100ng/ml) was added at for various time points and RNA samples were analyzed 
using qRT-PCR as outlined in the materials and methods. Values are normalized 
to RPL13A.  C. miR155 expression following IFN-α  (1000IU/ml) for 6h.  Values 
























































IFN-α suppresses insulin mediated NO production in response to acute 
treatment  
 
To further understand the impact of IFNα mediated changes in eNOS phosphorylation 
following acute treatment, we examined NO production as well as changes in cGMP.  
Insulin stimulated cultured HUVEC NO production almost 3-old.  IFN-α treatment did 
not significantly impair unstimulated NO production at early time points.  However, IFN-
α greatly impaired insulin-mediated NO production by 53%, 60%, and 44% at 15, 30, and 
60 minutes, respectively  (Figure 5-12A,B).  Further supporting the notion that IFNα does 
not significantly basal NO levels, results from our cGMP assay indicated that IFNα had 













Figure 5-12. IFN-alpha impairs insulin mediated NO production. A. 
Cells were incubated with IFN-α at 15, 30, and 60 minutes and loaded with 
1uM DAF-FM diacetate, a nitric oxide sensitive dye. Cells were incubated 
with or without insulin for 30 minutes and samples were analyzed using the 
flow cytometer. Histograms displaying DAF-FM intensity of 1 representative 
buffer control, 1 representative insulin  (100nM), 1 representative IFNα 
treatment, and 1 representative IFNα and insulin  (100nM) treatment group.  
Total events for acquisition were 10,000 for all treatment groups and cells 
were gate on live cells based on propidium iodide stain and DAF-FM 
diacetate stain. B. The graph represents mean fold change ± SD of the 
median fluorescence intensity  (MFI) of 4 independent experiments. Data was 
analyzed using a Two-way Anova and Bonferonni’s posttest. *p<0.05, 
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IFN-α induces eNOS phosphorylation in vitro 
Post-translational modifications in response to G-protein receptor agonists such as 
insulin regulate eNOS activity and NO synthesis.  Insulin activates eNOS via 
phosphorylation at the serine 1177  (Ser1177)223 site, and by inducing desphosphorylation 
at the negative regulatory site, threonine 495  (Thr495 )318.   Due to changes in eNOS 
mRNA and protein levels at 6 and 24 hours, examining phosphorylation after late time 
points would present another level of complexity, as changes in protein expression 
upstream make it difficult to distinguish the mechanism whereby NO is diminished. 
Furthermore, evidence suggests that eNOS phosphorylation is typically expedient and 
transient. Early timed studies indicated that changes in NO were greatest at the 30-minute 
time point.  Therefore, the 30 minute treatment model was used in the remaining studies.  
 Insulin potentiated phosphorylation at the Ser1177 site  (Insulin: 1.5±0.56 vs. 
Control 1.0±0.033) as well as the Thr495 site  (Insulin: 1.5±0.34 vs. Control 1.00±0.03, 
p<0.05; Figure 5-13A-C.  This is contrary to previously published findings suggesting 
that insulin impairs pThr495 phosphorylation 61. IFN-α  (1000IU/ml) treatment 
surprisingly induced phosphorylation at the Ser1177  (IFNα: 1.3±0.33 vs Control: 
1.00±0.003, p<0.05).  Further, phosphorylation at the Thr495 site was significantly 
increased  (IFNα: 1.99± 1.06 vs Control: 1.00±0.03, p<0.05).  Further, insulin suppressed 
IFNα mediated inductions in Thr495 phosphorylation  (IFNα + Insulin: 1.27± 0.43) while 
enhancing phosphorylation at the Ser1177 site  (IFNα + Insulin: 1.51 ± 0.65).  However, 
these changes were not significant  (Figure 5-13A-C). Taken together, these data suggest 
that IFNα may cause eNOS phosphorylation to shift from its active to inactive state but, 
insulin does not have the capacity to restore the normal phosphorylation paradigm as 
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evidenced by loss of NO production. This would suggest that IFN-α induces insulin 


















Figure 5-13. IFN-alpha promotes Thr495 phosphorylation. A. Cell 
lysates were  immunoblotted for eNOS, p-Ser1177 or p-Thr495 following 
a 30 minute IFNα stimulation. Blots are representative of 3-6 
independent experiments. B. Fold expression of quantified 
phosphoeNOS/eNOS bands normalized to control.  Means ± SD of the 
fold change, normalized to eNOS are reported.  n=3-9. *p<0.05. 
Western blot data was analyzed using a Two-way ANOVA and 
































































Summary of Findings 
The main finding of our study is that IFNα decreases NOS3 mRNA expression, 
protein expression, and insulin-mediated NO production by decreasing NOS3 mRNA 
stability, possibly through NF-kB mediated miR155 expression. Many studies support the 
critical role of Type I IFNs in the pathogenesis of lupus as well as secondary clinical 
manifestations of the disease. Moreover, a number of studies have shown links between 
Type I IFN signature gene expression in peripheral blood mononuclear cells and 
endothelial dysfunction.  For the first time, we’ve shown that IFNα modulates eNOS 
which is important for endothelial cell homeostasis and function  (Schematic 5-1).  
 
Interferon Signature Gene Induction 
Physiologically relevant concentrations of IFNα are difficult to discern given the 
lack of sensitivity and specificity of ELISAs296. Thus, we rely on interferon signature 
gene induction to understand translatable concentrations for in vitro studies.  For the first 
time, we’ve shown that 1000IU/ml IFNα and 20% SLE serum induces MX1 and PKR 
interferon signature genes in a similar manner thus, we used 1000IU IFNα for our studies.  
Previous studies in WISH cells have shown MX1 and IFIT1 induction levels are quite 
different than what we found depending on the concentration of serum and/or IFN296.  
This may be due to the physiology of endothelial vs epithelial cells including other 
proteins and genes expressed in cells, IFNAR expression on the cell surface, etc.  
However, it is unlikely that IFN-α in SLE serum is the only inducer of our 
selected IFIGs in endothelial cells. Nevertheless, previous studies suggest that it may be 
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the dominant mediator upstream of PRKR and MX1 specific transcription. A number of 
cytokines and chemokines present in SLE serum may also impact expression of IFIGs, 
including IFNβ, IFNλ, or IFNγ, which all partially contribute to PRKR expression 319. 
Moreover, Cates et. al., 2014 showed that IL-10 synergizes with IFN-α to amplify its 
effects on impaired endothelial progenitor cell function 320. The presence of dsDNA  
(CpG) immune complexes or viral agents containing dsRNA present in patient blood may 
also lead to activation of toll-like receptor  (TLR) signaling pathways that further induce 
IFN-α signature gene induction321.  
 
Interferon alpha impairs eNOS expression 
 Multiple studies have shown that IFN-α is a potent pro-atherogenic factor; 
however, its impacts on early stage atherogenesis or endothelial dysfunction are only 
recently being investigated. In this study, we demonstrated that IFN-α exerts its 
deleterious effects on endothelial function in part through suppression of eNOS/NOS3 
gene expression. Furthermore, these changes negatively correlated with both IFNα and 
SLE serum induction of PRKR and but only IFNα induced MX1.  
These findings are supported by a previous study that reported an association 
between SLE serum mediated PRKR induction in WISH cells and reduced brachial artery 
flow mediated dilation, a surrogate marker of endothelial dysfunction 322. Moreover, 
lupus endothelial progenitor cell  (EPC) circulation and function are impaired in 
association with high type I IFIG ex vivo. Mobilization of EPCs is regulated by eNOS. 
Thus, one potential mechanism whereby EPC circulation is impaired in SLE patients is 
through type I interferon downregulation of eNOS expression. Yet, controversy exists as 
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to whether or not eNOS gene expression impacts endothelial function and nitric oxide 
production. In hyperglycemia and diabetes, eNOS levels are increased, decreased, or 
unchanged. Moreover, when levels increase, they are typically associated with a rise in 
superoxide production and are likely increased to compensate for loss of NO 
bioavailability 323.  
Our studies also showed a significant decline in eNOS protein expression in 
response to IFNα . Moreover, these cells had enhanced phosphorylation at the Ser1177 site 
and the Thr495 site and subsequent declines in NO followed.  Nitric oxide bioavailability 
is modified based on a number of factors including enzyme expression and activity.  Thus, 
changes in eNOS expression may have lead to altered NO production.  Our studies are 
limited due to lack of eNOS activity measurements.  Furthermore, given that NOS3 
mRNA abundance was significantly suppressed at both 6 and 24h, but NO production 
was only impacted at 6h might suggest a role for iNOS induction.  However, we did not 
detect iNOS  (NOS2) induction in our cell cultures.  
Our findings contradict a previous study showing that IFN-α2b had no impact on 
eNOS expression or NO production 324. Our studies differ from this one in that they were 
conducted in HUVECs. However, preliminary findings in HAECs showed an even more 
drastic impact of IFN-α on eNOS expression after 24hr treatment at 1000IU/ml. 
Moreover, the authors measured nitrate/nitrite levels reported in the micromolar range. 
Given that NO produced by eNOS is measured in the nanomolar range, it is difficult to 
detect eNOS NO using this type of assay when background levels are in the micromolar 




One possible mechanism whereby IFN-α may impair insulin-mediated up 
regulation of NO production is through PKR induction. Prior studies showed that PKR 
phosphorylates the insulin receptor substrate 1  (IRS1) at Ser312, an inhibitory site, and 
suppresses phosphorylation at that activation site, Tyr941 leading to loss of downstream 
signaling 326. Thus, upregulation of PKR may be responsible for impaired insulin 
mediated NO production. However, we did not assess IFNα mediated changes in NO in 
PKR deficient cells. 
NO is an anti-atherogenic molecule, with multiple downstream targets including 
adhesion molecules, chemokines, and cyclic guanosine monophosphate. NO exerts it 
anti-atherogenic effects by inhibiting NF-κB activation in two different ways. NO 
promotes IκB expression preventing NF-κB activation while S-nitrosylating the cysteine 
group located on p50. Collectively, these mechanisms prevent nuclear localization of NF-
κB and subsequent upregulation of ICAM-1, VCAM-1, and MCP-1 associated with 
atherogenic plaque formation.  We showed that IFNα stimulation enhances adhesion 
molecule expression and MCP-1 production; but, enhanced neutrophil adhesion to the 
endothelial cell surface was not significant. MCP-1 and VCAM-1 are important for 
leukocyte adhesion to the endothelial cell surface including monocytes which our studies 
failed to examine.   
. Collectively, these studies suggest that IFN-α perpetuates endothelial 
dysfunction as evidenced by loss of NO production and upregulation of targets generally 




To further understand the in vivo relevance of our findings, we compared changes 
in SLE mediated induction of PKR expression to changes in NOS3 mRNA showed a 
strong negative association between the two genes suggesting a possible intrinsic co-
regulation by IFNα. However, our experiments in which PKR induction was blocked by 
siRNA indicated that eNOS expression was not regulated by PKR. This suggests that the 
effect is not at the level of expression.   
PKR phosphorylates IKK independent of dsRNA-mediated activation, leading to 
phosphorylation of IκB-α and subsequent activation of NF-κB. Conversely, the NF-kB 
p50 subunit promotes eNOS transcription by binding to the shear stress response element  
(SSRE) in the eNOS promoter region. Surprisingly, we found that siRNA-mediated 
knockdown of PRKR led to further reductions in eNOS mRNA levels and NFκB  (Figure 
5-8A-C), suggesting a possible protective role for PKR. 
Further, we observed that NFκB knockdown resulted in a 1.5 fold increase in 
eNOS mRNA compared to IFN-α stimulated controls. NF-κB was previously shown to 
upregulate eNOS transcription during shear stress by binding to the SSRE promoter 
region.  Conversely, NF-κB activation enhances IL-1b, IL-6, and TNFα production.  
These cytokines antagonize eNOS protein or gene expression via destabilization or 
changes in eNOS transcription rates  (Figure 5-8C). Thus, NF-KB may be regulating 
eNOS expression indirectly. However, these studies do not address these mechanisms. 
NF-kB has pleiotropic effects on eNOS expression at both the transcription and 
post-transcriptional modifications levels.  Our studies showed that transcription was 
unchanged in response to IFNα. This led us to examine changes in NOS3 mRNA stability 
where we observed decreases eNOS half-life with IFNα stimulation.  As an anti-viral 
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cytokine, IFNα is known to activate pathways that limit intracellular viral replication 
possibly through alterations in gene stability.  Previous studies have reported that IFNα 
and NF-kB induce miRs known to destabilize eNOS including miR155317, 327  
Previous studies have shown that miR155 is upregulated in atherosclerotic 
plaques isolated from patients with coronary artery disease. Moreover, as previously 
stated, miR155 overexpressed in HUVECs drastically reduced eNOS expression and NO 
production by decreasing eNOS mRNA stability by binding to the 3’UTR region. 
Cytokines such as TNF-α have previously been shown to induce miR155 expression in a 
NF-κB dependent manner. Here, our studies demonstrated that treatment with IFN-α 
induced miR155 expression which may explain the amelioration observed in eNOS gene 
expression over time. To date, studies examining upregulation of miR155 in SLE patient 
plaques and EPCs are missing. Our preliminary studies engender the hypothesis that 
miR155 upregulation in endothelial cells by IFN-α serves as one possible mechanism 
whereby endothelial dysfunction ensues in vivo. Further studies need to be conducted to 
determine factors at play downstream of PKR and NFκB, which lead to, increases 
miR155 expression.  
 Systemic lupus erythematosus patients have interferon inducible gene expression 
in PBMCs that correlated in disease activity and endothelial dysfunction.  This is the first 
study to demonstrate that that IFNα impairs insulin mediated NO production in 
endothelial cells.  Moreover, we show that mechanisms leading to reduce NO include 
loss of eNOS mRNA, protein, and possibly alterations in eNOS phosphorylation. Novel 
mechanisms leading to increased eNOS instability by IFN alpha may be NF-kB/miR155 
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mediated.  Future studies examining changes in eNOS genetically in IFNAR deficient 
NZM/NZW animal models may provide insight on the impact of IFNs on eNOS in vivo. 
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Schematic 5—1. Recombinant IFNα negatively regulates eNOS and suppresses NO 
production in human umbilical vein endothelial cells.  IFNα suppresses NOS3 mRNA 
stability resulting in loss of eNOS protein and NO production.  One possible mechanism 
leading to impaired NOS3 mRNA stability is up regulation of NF-kB.  NF-kB may lead to 
impaired NOS3 expression via increases in miR155.  IFNα impairs insulin mediated NO 
production possibly by increasing phosphorylation at the Thr495 site. Losses in NO 
production yield diminished cGMP production.  IFN-α treatment up regulates MCP-1 as 
previously shown in the literature and up regulates VCAM-1 and ICAM-1 gene 
expression. However, increases in adhesion molecule expression does not yield elevated 
neutrophil adhesion to the endothelial cell surface.  





     
















Over the past 60 years, with large-scale socioeconomic improvements, morbidity 
and mortality rates in SLE patients have slowly declined.  On the other hand, 
cardiovascular disease rates have increased drastically and are now the leading cause of 
morbidity and mortality in non-autoimmune and in SLE populations. Synergy between 
chronic inflammation and the development of atherosclerosis results in a more 
accelerated and aggressive form of disease, leading to greater morbidity in SLE patients.  
Although the cause of advanced disease is unknown, it is well established that damage to 
the vasculature precedes atherosclerotic plaque development.  
Vascular biology encompasses the study of vascular cells, including smooth 
muscle cells and endothelial cells. In the past 35 years, since the discovery of NO by 
Furchgott, Ignarro, and Murad, studies examining the endothelium show its obligatory 
role in maintaining cardiovascular homeostasis 328, 329, 330 {Ignarro, 1980 #8146. The 
prominent L-arginine/NO pathway requiring BH4 appears to be a key mediator of 
vascular health. 
The roles of endothelial-derived NO range from cGMP-mediated vasorelaxation 
to  aiding in endothelial progenitor cell and bone marrow cell homing injured sites within 
the vasculature  331, 332. Studies in SLE patients have shown a disproportionate increase in 
vascular endothelial dysfunction; however the etiology is unclear. 
The emerging question following these observations was which SLE specific 
factors contribute to impaired endothelial function and worse disease prognosis. A pattern 
of increased injury and impaired repair mechanisms has been proposed and associated 
with increases in type I interferon signature gene expression in peripheral blood 
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mononuclear cells. While others reported increases in conventional cardiovascular risk 
factors such as hypercholesterolemia and dyslipidemia that may promote accelerated 
disease, several more SLE-specific factors exist that could potentially account for a 
reduction in endothelial-dependent vascular function.  Therefore, identification of triggers 
leading to accelerated atherosclerotic plaque development in this complex and 
heterogeneous disease is difficult. 
Coupling and Uncoupling: A possible mechanism of endothelial dysfunction 
in SLE 
Increasing evidence points to a role for eNOS uncoupling, yielding increased 
degradation and reduced production, in the pathogenesis of endothelial dysfunction.  
Properly functioning eNOS converts L-arginine to L- citrulline and NO through a series 
of oxidative steps.  A key co-factor in this enzymatic process is BH4, which is diminished 
under pathophysiologic conditions marked by oxidative stress  333, 334. Seemingly 
paradoxical, oxidative stress promotes increases in NOS3 gene expression due to 
enhanced H2O2-mediated transcriptional regulation in the vascular microenvironment. 
Our findings support the hypothesis that eNOS uncoupling may serve as one 
mechanism of endothelial dysfunction. Briefly, SLE serum increased NOS3 mRNA 
expression over control serum in cultured HUVECs. Initially, these findings seemed 
contradictory to previous studies from our lab showing that eNOS deficiency was 
pathogenic in the lupus microenvironment 287, 335. Moreover, SLE serum suppressed 
HUVEC NO production even with increased NOS3 gene expression. Our experiments 
failed to measure oxidative stress and NADPH oxidase activity in vitro; however, the 
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literature suggests that the observed paradigm in our studies may result from oxidative 
stress induced eNOS uncoupling.  Oxidative stress, in the form of superoxide, rapidly 
reacts with NO to form peroxynitrite.  This molecule deactivates BH4 through its 
oxidation to BH2.  BH4 is essential for stabilizing the eNOS dimer and facilitating transfer 
of electrons from the reductase to the oxygenase domain.  Our experiments also failed to 
measure BH4; however, we conducted BH4 repletion experiments, using L-sepiapterin, to 
examine changes in eNOS coupling in the presence of serum.  Indeed, L-sepiapterin, a 
BH4 precursor, restored SLE serum-mediated reductions in NO production from 
HUVECs. These findings demonstrate that SLE serum may promote oxidative stress in 
vitro, leading to eNOS uncoupling. Also, eNOS uncoupling leads to loss of NO 
bioactivity, which is restored, with L-sepiapterin.  
 Quite remarkably, administration of BH4 in LDL-cultured endothelial cells 
prevented uncoupling of eNOS336. In contrast, sepiapterin supplementation in vivo led to 
enhanced eNOS uncoupling due to competitive binding with BH4337. Thus, 
upplementation with L-sepiapterin may be most effective in more severe cases of 
oxidative stress where BH4 is deficient. Whether or not L-sepiapterin is actually working 
to restore eNOS coupling in our in vitro model was not addressed.  However, our 
preliminary findings suggest that L- sepiapterin is effective in restoring NO production, 
regardless of culture conditions.  Thus, L-sepiapterin may serve as a logical therapeutic 
option for SLE-related endothelial dysfunction.  
Molecular pathways involved in endothelial dysfunction are diverse and 
pleiotropic. For example, NF-kB activation yields enhanced adhesion molecule 
expression and subsequent leukocyte adhesion to the endothelial cell surface. Moreover, 
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increases in H2O2 have been shown to enhance ICAM-1 and IL-8 expression in various 
endothelial cell types.  The observation that SLE serum induced neutrophil adhesion to 
the endothelial cell surface may suggest that NO concentrations are too low to impact 
downstream targets. Surprisingly, L-sepiapterin supplementation was not able to 
significantly reverse these changes.  A titration study designed to assess therapeutic 
dosing of L-sepiapterin in vitro would provide insight on whether our initial results were 
due to inadequate L-sepiapterin concentrations.  In addition, these studies will allow 
assessment of the oxidative stress load and provide insight on other possible sources of 
superoxide genesis.  
In addition to our initial group of studies, we conducted a stratified analysis of 
healthy and lupus serum effects on neutrophil chemotaxis, a functional consequence of 
increases in IL-8 production. Our results show that serum from patients with SLE 
significantly induces neutrophil chemotaxis over healthy controls. Endothelial cells are 
the major producer of IL-8; however, the relationship between IL-8 and endothelial 
derived-NO has only been investigated recently. Thus far, IL-8 has been shown to 
enhance IL-8  but, no effect of IL-8 on nitric oxide production has been shown. Further, 
IL-8 elicits plasminogen activator inhibitor-1  (PAI-1) expression in HUVECs, giving the 
cells increased coagulative capacity 338. Controversy exists as to the role of NO in 
modulating IL-8 production. While early studies showed that impaired NO production 
resulted in increased leukocyte adhesion to the endothelial cell surface, other studies have 
suggested that NO promotes cGMP production, leading to upregulation of IL-8 mRNA 




S-nitrosation of cysteine 62 and 179 of the NFkB p50 subunit and IKKβ of the 
p65 NFκB subunit renders the protein inactive.  Moreover, studies show that S- 
nitrosylation can occur at the p65 subunit as well 226, 315, 316, 339, 340. Thus, with enhanced 
low nanomolar NO production, NF-κB activity is compromised, further reducing 
inflammation.  Studies designed to determine NO concentrations for impairing NFκB-
mediated neutrophil adhesion in our model were lacking. 
Collectively, these data point to role for SLE serum-mediated eNOS uncoupling. 
However, results from these studies must be interpreted in context. Lack of shear stress 
serves as one limitation associated with in vitro endothelial cell culture since it induces 
endothelial abnormalities in and of itself. SLE- mediated endothelial dysfunction is a real 
phenomenon in vivo. eNOS uncoupling may be a pathogenic mechanism in this process, 
and therapies that restore eNOS coupling and reduce other endothelial sources of 
oxidative signaling may be beneficial in preventing endothelial dysfunction observed in 
SLE patients. 
Future Directions 
Studies similar to ours have investigated the relationship between brachial artery 
flow mediated dilation and NO production in vitro, suggesting that serum factors 
contribute to modulation of eNOS in vitro. Further, in vitro changes induced by serum 
may parallel clinical measurements of FMD. Preliminary data from our studies show 
trends towards an association between eNOS, NO and FMD; however our studies remain 
inconclusive  (Figure 6-1A,B).  
We also showed L-sepiapterin mediated reversal in serum-induced reductions in 
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NO. These findings warrant further research examining changes in BH4 in response to 
SLE serum treatment. The extent to which MRL/lpr and NZM/NZW mice develop eNOS 
uncoupling is not clearly understood. Thus studies examining eNOS uncoupling and L-
sepiapterin efficacy in reversing vascular complications may provide useful information 
for treating SLE patients with endothelial dysfunction.  
Preliminary data implicates a possible role for oxidative stress in eNOS 
uncoupling. Thus, investigations regarding superoxide production along with NADPH 
oxidase activity warrant assessment.   Tools that we could potentially employ for these 
experiments include: NADPH oxidase inhibitors such as apocynin, VAS2870, or 
diphenylene iodonium  (DPI) and fluorescent superoxide probes. Parallel experiments 
should assess changes in serum induced peroxynitrite  (ONOO- )and iNOS derived NO 
production.   
Functional consequences of subpar NO levels include leukocyte migration and 
adhesion, both of which were evident in response to SLE serum. Future studies are 
needed to tease out the role of SLE serum in mediating these pathways of IL- 8 
production, neutrophil adhesion, and NO bioavailability. Studies should also measure 
cytokine and chemokine changes induced by SLE serum that may prompt leukocyte 
migration and adherence.  
L-sepiapterin supplementation failed to reverse leukocyte adhesion. This finding 
warrants future L-sepiapterin titration experiments that assess correlations between NO 
concentration  (as measured by a Griess assay) and leukocyte adhesion in the presence of 
SLE serum.  
Lastly, SLE serum fractionation by size, protein A/G depletion, or removal of 
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abundant proteins will help identify serum factors responsible for diminished NO 
production. Preliminary studies in our lab point to a role for IgG in mediating changes in 
NO production, while interferon alpha neutralization studies appear to reverse SLE serum 
































Figure 6-1. Correlative assessment of brachial artery flow mediated dilation 
with in vitro changes. A.  HUVECs were cultured as previously described and 
treated with 50% serum from SLE patients for 6hr.  NO production was assessed 
using DAF-FM diacetate.  A total of 7,000 events were collected and changes in 
fluorescence are expression as median fluorescence intensity.  All values were 
normalized to buffer control and plotted as a function of brachial artery FMD 
assessed on the same day as the serum sample collection of 8 SLE patients.  B.  
NOS3 mRNA expression plotted as a function of FMD of 8 SLE patients.  These 
studies were under powered for accurate analysis but provide insight on possible 


































Figure 6-2. Nitric oxide production in IgG-fractionated serum treated 
HUVECs. A-B. Cells were treated with 50% healthy or SLE serum ± IgG 
fractionation and ± insulin treatment  (100nM).  Removal of IgG promoted basal 
NO production and insulin mediated NO production in SLE serum treated cells but 





















A novel role for IFNα in eNOS dysfunction and insulin –resistance 
 
The secondary goal of our study was to determine the impact of lupus-specific 
factors that might explain premature cardiovascular diseases in our patient population. 
We discovered that IFNα negatively regulated eNOS gene expression and that these 
changes correlated with PKR and MX1.  These observations raised the hypothesis that 
IFN-α might be responsible suppression of eNOS in vitro. Excitingly, associations 
between eNOS expression and PKR induction by rIFNα paralleled human serum 
mediated changes. 
Basal NO and insulin-mediated production declined in response to rIFNα, 
possibly due suppressed protein expression. Insulin resistance is increased in patients 
with SLE. Thus, for the first time, our studies may explain a novel mechanism whereby 
insulin resistance occurs in SLE, despite the absence of conventional risk factors.  These 
findings are supported by previous observations that Type I interferon signature gene 
induction correlate with reduced FMD and declines in EPC circulation , both of which 
dependent on adequate endothelial derived NO. 
IFNα impaired cGMP production, a functional consequence of diminished NO 
levels. Accordingly, IFNα induced ICAM-1, VCAM-1, and MCP-1 production; yet, only 
a slight increase in neutrophil adhesion occurred. Thus, IFNα is not sufficient to 
significantly increase endothelial cell stickiness. These data support the hypothesis that 
interplay and crosstalk amongst several SLE factors promote a pro-atherogenic 
phenotype in vitro, with IFNα serving as a key player.  
PKR deficient cells decreased in eNOS expression in response to IFNα, while 
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eNOS levels in NFκB deficient cells treated with rIFNα were restored. NF-κB has 
pleiotropic effects on eNOS including: modulation of shear stress induced eNOS, 
induction of eNOS antagonists  (TNFα, IL-1β) and upregulation of the eNOS destabilizer 
microRNA 155. MiR155 upregulation by rIFNα in our cultures coincided with previous 
findings that rIFNα modulated miR155 expression in dendritic cells 341. A regulator of 
NOS3 mRNA stability, MiR155 is a key player in cardiovascular disease 342 and may be a 
novel factor in SLE related vasculopathies. Further confirming the role of miR155 in 
these pathways, we examined changes in eNOS mRNA stability in response to IFNα and 
observed a significant reduction. Collectively, these data provide the rationale for further 
studies investigating miR155 expression in patients with SLE.  
Post-translational modifications  (i.e. pThr495 and pSer1177) largely influence NO 
production. In response to rIFNα, we observed enhanced pThr495, which may account for 
declines in basal and insulin mediated NO production. Previous studies support these 
findings as PKR induced by IFNα prevents insulin receptor activation via inhibitory 
phosphorylation at Ser312, leading to subsequent inhibition of phosphorylation at the 
activation site, Tyr941326. Future studies examining IFNα/insulin mediated signaling in 
PKR deficient endothelial cells are needed. 
Insulin signaling occurs through the PI3K/Akt pathway leading to 
phosphorylation at the Ser1177 site. We did not observe significant alterations in Ser1177 
phosphorylation in response to IFNα treatment.  Moreover, insulin was recently reported 
to prevent phosphorylation of eNOS at the Thr495 site through activation of PP1. Our 
studies did not define mechanisms through which IFNα induces insulin sensitivity, but 




Upon examination of functional outcomes of diminished NO, we did not observe 
decreases in cGMP at early but did during late time points, suggesting that effects of 
deficient NO on cGMP production are a late rather than early event.  Further, these 
studies might suggest that IFNα does not activate the cGMP phosphodiesterase type 5, 
which could result in diminished cGMP bioavailability with acute treatment. However, 
further studies are needed to confirm this finding. 
Future Directions 
A key limitation in our studies was the absence of shear stress in vitro which 
mimics blood flow across the endothelial cell layer. Shear stress activates eNOS and 
serves as a major factor in vascular homeostasis. Thus, incorporating flow chambers into 
our studies may provide stronger evidence for IFNα mediated eNOS suppression. 
Another limitation of our studies was the absence of other IFNα subtypes including α2b, 
α4, etc. Thus, future studies might examine the impact of all factors on eNOS expression, 
activation, and NO production. Finally, our studies utilized HUVECs, which are limited 
in their ability to provide information on the effect of cytokines and chemokines on 
vascular endothelial cell complications. Preliminary data in human aortic endothelial 
cells showed that IFNα negatively affects eNOS expression  (Figure 6-3A); however, 
these studies are not powered to draw conclusions. 
Animal models examining the role of miR155 in lupus associated CVD are 
missing. Our preliminary data show that miR155 may be essential in IFNα-mediated 
eNOS expression, driving the hypothesis that miR155 suppression may improve vascular 
complications in IFNα dependent NZM/NZW lupus mouse models. Further, in vitro 
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using NF-kB inhibitors and a miR155 antagonist may clarify the relationship between 
these two modulators that promote IFNα dependent eNOS alterations.  
Activation of eNOS is key for NO production, however our studies did not 
examine eNOS activation. Thus, using activity assays, future studies should delve into 
the impact of IFNα on eNOS activity by possibly examining the conversion of L-
citrulline to L-arginine. Further PI3K/Akt, PP1, PP2A, and PKC expression and 
phosphorylation/activation are possibly affected by IFNα. Thus, future studies could 
examine these pathways to further understand how IFNα might exploit these proteins to 
impair eNOS- NO capacity.  
Finally, our studies failed to assess IFNα induced oxidative stress in our HUVEC 
cultures; although, we did measure NOX4 levels and did not observe any differences 
between the treated and non-treated groups  (Figure 6-3B). Thus, future studies 
investigating IFNα mediated changes in oxidative stress may provide insight on losses in 








































Figure 6-3. NOS3 and NOX4 gene expression in human aortic endothelial 
cells or HUVECs treated with IFNα. A. The graph represents the mean fold 
change ± SD in NOS3 expression in HAECs stimulated for 24 hours.  All samples 
are normalized to GAPDH. B. mRNA expression of NOX4 in HUVECs 
stimulated for 6 hours. All samples were normalized to GAPDH and bars 











Given the initial findings in the first portion of our research, it is evident that 
eNOS uncoupling may be important in SLE-mediated endothelial dysfunction. However, 
we did not examine the effect of IFNα in these pathways. The IFNα-oxidative stress axis 
is complex, as multiple studies propose a regulatory loop whereby oxidation and 
nitrosylation of inflammatory protein mediators interact to oppose each other. Thus, 
future studies examining the cross-talk between interferon alpha and oxidative stress are 




Impact on Field 
Atherosclerosis is a public health concern that impacts non-autoimmune and auto- 
immune disease populations alike. In addition to Mariana Kaplan’s extensive work on 
IFNα in EPCs, we now know that IFNα modulates NO, the key regulator of endothelial 
function. The effect of IFNα on insulin sensitivity is a critical finding. Further, we 
understand that one potential mechanism whereby endothelial dysfunction in SLE 
patients occurs is through eNOS uncoupling. Pre-clinical studies examining the efficacy 
of IFNAR antibodies, BH4 supplementation, as well as other targets impacting eNOS 
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